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SUMMARY 
During the past few years, a large number of studies have explored the value of gene 
expression profiling in breast cancer (BC), revealing the existence of at least four major 
molecular subtypes with different clinical features (luminal A, luminal B, Her2 and triple 
negative (TN)). However, few reports have investigated the usefulness of microRNA (miRNA) 
expression profiling in BC management. Given the important role that miRNAs play in 
tumorigenesis and their great potential as novel clinical biomarkers, we aimed to investigate 
their deregulation in BC and their diagnostic and prognostic utility. We performed miRNA 
expression profiling in a large series of primary breast tumors and normal breast tissues, and 
identified a number of miRNAs commonly and specifically deregulated in the four subtypes, 
many of them not previously reported. In addition, five miRNA signatures that discriminate 
breast tumors and BC molecular subtypes with high sensitivity and specificity were defined. 
We hypothesize that these signatures might be informative for BC diagnosis. The most 
relevant tumoral miRNAs were analyzed in two independent series of plasma. MiR-505-5p, 
miR-125b-5p, miR-21-5p and miR-96-5p were confirmed to be overexpressed in the plasma 
of BC patients when compared with healthy women (AUC=0.61-0.72), and we found that the 
levels of miR-505-5p and miR-21-5p decreased in a group of treated patients. Our results 
demonstrate the potential utility of these miRNAs as non-invasive biomarkers for early BC 
detection. We have also defined a set of 17 miRNAs that are downregulated in breast 
tumors of node-positive TN patients with poor outcome. Moreover, we found that miR-30c-
5p and miR-195-5p are associated with recurrence, and that miR-195-5p might be an 
independent prognostic marker in triple negative breast cancer (TNBC). Thus, analysis of 
miR-195-5p expression could serve to define a group of TN patients who may benefit from a 
more aggressive therapy. Finally, we found that two miRNAs that are specifically 
overexpressed in TN tumors, miR-498 and miR-187-5p, target the 3'UTR of the BRCA1 gene. 
Furthermore, we demonstrated that miR-498 regulates BRCA1 expression in BC cell lines 
and its inhibition leads to reduced proliferation in TNBC cells. These results shed light on the 
mechanisms behind the decreased expression of BRCA1 in sporadic TNBC. In summary, our 
findings bring new insights in the deregulation of miRNAs in BC molecular subtypes and 
their potential use as BC biomarkers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
RESUMEN 
En los últimos años numerosos estudios han investigado el valor de los perfiles de 
expresión génica en el cáncer de mama (CM), revelando la existencia de al menos cuatro 
subtipos moleculares con distintas características clínicas (luminal A, luminal B, Her2 y triple 
negativo (TN)). Sin embargo, pocas investigaciones han explorado la utilidad de los perfiles 
de expresión de microRNAs (miRNA) en el manejo del CM. Teniendo en cuenta el 
importante papel que los miRNAs juegan en la carcinogénesis y su gran potencial como 
nuevos biomarcadores, el objetivo de esta tesis ha sido investigar su desregulación en CM y 
su utilidad diagnóstica y pronóstica. Hemos obtenido los perfiles de expresión de miRNAs de 
una gran serie de tumores primarios de mama y tejidos mamarios normales, y hemos 
identificado miRNAs comúnmente y específicamente desregulados en los cuatro subtipos, 
muchos de ellos no reportados hasta el momento. Además hemos definido cinco firmas de 
miRNAs que discriminan los tumores de mama y los subtipos moleculares de CM con gran 
sensibilidad y especificidad. Los miRNAs tumorales más relevantes fueron analizados en dos 
series independientes de plasmas, confirmándose la sobreexpresión de los miR-505-5p, 
miR-125b-5p, miR-21-5p y miR-96-5p en el plasma de pacientes con CM en comparación con 
mujeres sanas (AUC=0.61-0.72). Además, los niveles de expresión de los miR-505-5p y miR-
21-5p disminuyeron en un grupo de pacientes tratadas. Nuestros resultados demuestran la 
posible utilidad de estos miRNAs como biomarcadores no invasivos para la detección 
temprana del CM. También hemos definido un conjunto de 17 miRNAs que están 
infraexpresados en tumores de mama de pacientes TN con ganglios positivos y mal 
pronóstico. Además, hemos encontrado que los miR-30c-5p y miR-195-5p están asociados 
con recurrencia y que el miR-195-5p podría ser un marcador de pronóstico independiente 
en cáncer de mama triple negativo (CMTN). De esta forma, el análisis de la expresión del 
miR-195-5p en tumores podría servir para definir un grupo de pacientes TN que podrían 
beneficiarse de una terapia más agresiva. Finalmente, hemos encontrado que dos miRNAs 
que están específicamente sobreexpresados en tumores TN, miR-498 y miR-187-5p, tienen 
como diana la región 3’UTR de BRCA1. Además, hemos demostrado que el miR-498 regula la 
expresión de BRCA1 en líneas celulares de CM, y que su inhibición da lugar a una reducción 
en la proliferación de las células TN. Estos resultados arrojan luz sobre los mecanismos 
responsables de la disminución en la expresión de BRCA1 en CMTN esporádico. En resumen, 
 
 
nuestros descubrimientos aportan nuevos conocimientos sobre la desregulación de los 
miRNAs en los subtipos moleculares de CM y sobre su posible uso como biomarcadores.   
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NPM1  Nucleophosmin (Nucleolar phosphoprotein B23, Numatrin) 
PALB2  Partner and localizer of BRCA2 
PARP   Poly (ADP-ribose) polymerase 
PBS  Phosphate buffer saline  
PCR  Polymerase chain reaction 
PIK3CA  Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha 
PI3K  Phosphatidylinositol 3-kinase 
PR  Progesterone receptor 
PTEN  Phosphatase and tensin homolog 
qRT-PCR Quantitative real-time PCR  
RAD50  RAD50 homolog (S. cerevisiae) 
RAD51  Recombination protein A 51 
RF  Random forest 
RFS  Relapse-free survival 
RISC  RNA-induced silencing complex 
RNA  Ribonucleic acid 
RNase  Ribonuclease 
ROC  Receiver operating characteristic 
ROR  Risk of relapse 
RPM  Rotations per minute 
RS  Recurrence score 
RT  Reverse transcriptase  
RT  Room temperature 
SDS  Sodium dodecyl sulfate  
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SNP  Single nucleotide polymorphism 
SRC  v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
STK11  Serine/threonine kinase 11 
SVM  Support vector machines  
TBS  Tris buffered saline 
TERT  Telomerase reverse transcriptase 
TGF-β  Transforming growth factor beta 
TN  Triple negative 
TNM  Tumor, node, metastasis 
TOP2A  Topoisomerase (DNA) II alpha 170kDa 
TP53  Tumor protein p53  
UTR  Untranslated region 
VEGF   Vascular endothelial growth factor  
WHO  World health organization 
WST-1  Water-soluble tetrazolium salt 
XRCC2  X-ray repair complementing defective repair in Chinese hamster cells 2 
YWHAZ  Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta
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1. BREAST CANCER 
1.1. Mammary gland and breast cancer 
The mammary gland is a highly specialized organ that is responsible for lactating. Both 
males and females have glandular tissue within the breasts, however, after puberty the 
glandular tissue begins to develop in response to estrogen release in females. The biological 
role of the mammary glands is to produce milk to nourish a newborn infant and to pass 
antibodies needed for infant’s protection against infections while the immature immune 
system is initiating its function.  
The mammary gland is formed by fifteen to twenty lobes that are arranged radially and 
delimited by septa of conjunctive tissue and adipose tissue in the subcutaneous layer 
(Figure 1A) (Ali and Coombes, 2002). Each lobe is formed by smaller functional units, the 
lobules, from which ducts converge towards the main duct of the lobe: the lactiferous duct. 
The lactiferous ducts are responsible for delivering the milk to the surface of the skin and 
out of the mother through tiny pores in the nipple (Hassiotou and Geddes, 2013). 
Ductal mammary epithelium is comprised of two layers of cells: a luminal/inner layer of 
secretory epithelial cells that enclose the ductal lumen, and a basal/outer layer of 
contractile myoepithelial cells that surround the luminal layer (Figure 1B) (Visvader, 2009). 
The basal layer lies on the basement membrane and is thought to contain multipotent 
mammary stem cells.  The epithelial ductal tree is embedded within a complex stroma, the 
mammary fat pad, which contains fibroblasts, adipocytes, blood vessels, nerves and various 
immune cells, all of which are important for normal mammary development and function 
(Hassiotou and Geddes, 2013). 
Breast cancer is a complex disease resulting from abnormal and disorganized 
proliferation of cells that compose breast tissue. About 95% of malignant breast tumors are 
carcinomas, which originate from the epithelium of the mammary gland. Carcinomas 
developing from the ducts are known as ductal carcinomas (the most common ones), while 
those developing from lobules are known as lobular carcinomas. Neoplastic transformation 
typically proceeds from a benign, well-differentiated localized tumor, carcinoma in situ, to 
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invasive cancer that penetrates basal membrane infiltrating the fatty tissue of the breast, 
and ultimately to metastatic tumor that disseminates to other parts of the body through 
lymphatic and blood vessels.  
 
Figure 1. A) Anatomy of the human mammary gland. Each mammary gland contains 15–20 lobes, 
each lobe containing a series of branched ducts that drain into the nipple (adapted from Ali and 
Coombes, 2002). B) Schematic representation of a terminal duct (adapted from Visvader, 2009).  
 
1.2. Epidemiology 
Worldwide, breast cancer is the second most frequent cancer and, by far, the most 
common cancer among women. In 2012 it was estimated that 1.67 million of women were 
diagnosed with breast cancer, accounting for one quarter of the total new cancer cases in 
women (Ferlay et al., 2014). Breast cancer is the most common cancer in women in both 
developing and developed regions, although incidence rates vary considerably across the 
world, with the highest rates in Western Europe (96 per 100,000) and the lowest in Middle 
Africa (27 per 100,000) (Figure 2) (Servick, 2014). This variation is likely due to differences in 
reproductive and hormonal factors and the availability of early detection services.  
Regarding mortality, breast cancer ranks as the fifth cause of death from cancer overall 
with 522,000 deaths estimated in 2012. It is the most deadly cancer in women in developing 
regions and the second cause in developed regions. The decrease in breast cancer death 
rates in developed countries over the last 25 years is a result of early detection through 
mammography, improvements in treatments and the implement of genetic testing (Ferlay 
et al., 2014). 
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Figure 2. Estimated age-standarized incidence and mortality rates of breast cancer per 100,000 
women in 2012 (adapted from Servick, 2014). 
 
1.3. Risk factors 
As breast cancer is a multifactorial disease, both genetic and non-genetic factors are 
involved in its development (Cuzick, 2008; McPherson et al., 2000). Being a woman is the 
main risk factor for breast cancer. Men can develop breast cancer, but this disease is about 
100 times more common among women than men. As with many other cancers, the 
incidence of breast cancer increases with age. About 2 out of 3 invasive breast cancers occur 
in women over the age of 55. Mammography density is an important factor in terms of 
breast cancer risk. Women with dense breasts (higher percentage of non-fatty tissue) are up 
to 5 times more likely to develop breast cancer compared with women with less dense 
breasts. In addition, dense breast tissue can make mammograms less accurate.  
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Family history and genetics are linked with increased breast cancer risk. Up to 7% of 
breast cancer cases are thought to be hereditary, with mutations in BRCA1 and BRCA2 genes 
accounting for a substantial proportion of high risk families. Having one first-degree relative 
(mother, sister or daughter) with breast cancer doubles a woman’s risk. The risk is further 
increased with a larger number of affected first-degree relatives or relatives who developed 
the disease before the age of 50. In addition, a woman with cancer in one breast has 3- to 4-
fold increased risk of developing a new cancer in the other breast or in another part of the 
same breast, and some types of benign breast disease are linked with increased breast 
cancer risk. Race and ethnicity also play a role in breast cancer incidence: studies show that 
white women are more likely to develop breast cancer than African American women, 
although African American women develop more aggressive breast tumors.  
Reproductive factors are well established risk factors for breast cancer. The modification 
of sex hormones levels (mainly estrogen exposure) may explain the link between these 
factors and breast cancer risk. Nulliparous women or women who have their first child after 
the age of 30 have a higher risk of breast cancer compared to women who gave birth before 
age 30. The relative risk increases by about 3% for each year older a woman is when she first 
gives birth. Subsequent births reduce relative risk by about 7% per birth. Breastfeeding is 
protective, especially if a woman breastfeeds for longer than 1 year. Breast cancer risk 
increases for each year younger at menarche and for each year older at menopause. 
Women using oral contraceptives and women using hormone replacement therapy for 
menopausal symptoms have slightly greater risk of breast cancer. Finally, lifestyle can 
influence the chances to develop breast cancer. Obesity is associated with a twofold 
increase in the risk of breast cancer in postmenopausal women. Saturated fat intake, lack of 
physical exercise, alcohol use and tobacco smoking are probable causes of breast cancer. 
1.4. Genetic susceptibility 
As mentioned before, positive family history is one of the most important risk factors for 
developing breast cancer. A large majority of breast cancer cases are sporadic, usually 
detected in older patients (>55 years), while approximately 5-7% of breast cancer cases 
arise in patients with strong familial aggregation of breast tumors with various affected 
members throughout several generations (Figure 3A) (Melchor and Benitez, 2013). These 
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families show an apparently dominant inheritance pattern and are characterized by an early 
age of onset, overrepresentation of ovarian cancers, bilateral breast cancers and/or male 
breast cancers. 
Current genetic landscape of breast cancer susceptibility consists of two rare high-
penetrance (>10-fold risk) susceptibility genes, several rare moderate-penetrance (2-4 fold 
risk) genes, and a large number of common low-penetrance (<1.5-fold risk) alleles 
(Ghoussaini et al., 2013). Family-based linkage analysis and positional cloning led to the 
identification of high-penetrance genes BRCA1 (Miki et al., 1994) and BRCA2 (Wooster et al., 
1994), two tumor-suppressor genes involved in DNA repair that may explain around 25% of 
familial breast cancer risk. Lifetime risks of breast and ovarian cancer by the age 70 years 
are 65 and 39%, respectively, among women carrying BRCA1 mutations, and 39 and 11% for 
BRCA2-mutation carriers. As tumor suppressor genes, mutation of both alleles is required 
for neoplastic transformation to occur. The mutation inherited through the germ line is 
often small and causes premature protein truncation, while the wild-type allele is usually 
lost somatically in the tumor cell (loss of heterozygosity). Cancer predisposition syndromes 
due to mutations in PTEN (Cowden syndrome), STK11 (Peutz-Jeghers syndrome), TP53 (Li-
Fraumeni syndrome) and CDH1 are also associated with high risk of breast cancer and 
account for 5% of the familial risk. Moderate-penetrance genes have been identified 
through their involvement in biological pathways that include BRCA1 and BRCA2, and have 
also been reported in about 5% of familial breast cancers. Such is the case of CHEK2, ATM, 
BRIP1, PALB2, RAD50, RAD51B, RAD51C, RAD51D, XRCC2 and NBS1. Finally, genome-wide 
tag SNP association studies have led to the identification of nearly one hundred common 
low-susceptibility loci (Michailidou et al., 2015). Unlike high-susceptibility genes, most of the 
variants identified in these loci are found in non-coding regions of the genome and are likely 
to involve regulation of genes in multiple pathways. These genes explain altogether around 
14% of familial cancer risk.  
Still, approximately half of familial breast cancer cases show no mutations in any of 
these genes, and are classified as BRCAX families (Figure 3B) (Melchor and Benitez, 2013). 
These families may either carry a mutation in a gene still not associated with breast cancer 
or be explained by additive low-penetrance loci (polygenic model). Modern sequencing 
technologies, analysis of non-coding RNA expression (such as microRNA and lncRNA) and 
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epigenetic studies will add more details to the description of the complex genetic architec-
ture underlying hereditary breast cancer. 
 
Figure 3. Genetic landscape of breast cancer susceptibility. A) A minor fraction of breast cancer cases 
are hereditary. B) Proportion of familial breast cancer patients explained by the 
identified susceptibility genes (adapted from Melchor and Benitez, 2013).  
 
2. BREAST CANCER HETEROGENEITY 
Breast cancer is a highly heterogeneous disease including a number of different entities 
with specific histopathological features, biological behaviors, clinical outcomes and 
responses to therapies. The identification of these entities is essential for cancer 
management since it allows for the categorization of patients into clinically relevant 
subgroups to aid prognostication and determine the appropriate therapy. Historically, 
breast cancer classification has been addressed with different perspectives, from the more 
traditional histopathological subgroups to the newer molecular subtypes.    
2.1. Histopathological classification 
Breast cancer is classified by pathologists on its histological appearance together with 
clinical and pathological factors. The histological classification of breast carcinoma is based 
on the wide range of morphological phenotypes that tumors exhibit. Many different 
histological types are described in the latest edition of the WHO classification of breast 
tumors (Lakhani et al., 2012), including invasive breast carcinomas, precursor lesions, lesions 
of low malignant potential, benign epithelial proliferations, fibroepithelial, myoepithelial 
and mesenchymal neoplasms, among others. Invasive breast carcinoma comprises 70-80% 
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of all cases and is a group of malignant epithelial tumors characterized by invasion of 
adjacent tissues and a marked tendency to metastasize to distant sites. Invasive carcinoma 
of no special type (previously known as invasive ductal carcinoma not otherwise specified) 
comprises the largest group of invasive breast cancers. It is a heterogeneous group of 
tumors that fail to exhibit sufficient characteristics to achieve classification as a specific 
histological type such as lobular, tubular, cribiform or mucinous carcinomas. A major 
disadvantage of this classification is that it is unable to reflect the much wider heterogeneity 
of breast cancer, because it groups within the same class tumors that have a very different 
biological and clinical profile. As a result, a variety of clinical and pathological factors are 
routinely used to categorize patients with breast cancer. 
Tumor grade is one of the most important tumor intrinsic characteristics that can be 
determined by histopathological analysis of breast cancer. The grade of a breast cancer is 
representative of the aggressive potential of the tumor, with low grade cancers tending to 
be less aggressive than high grade cancers. The grading system most widely used is the 
Nottingham Histologic Score system (the Elston-Ellis modification of Scarff-Bloom-
Richardson grading system) (Bloom and Richardson, 1957; Elston and Ellis, 1991). In this 
scoring system pathologists assess the degree of differentiation (tubule formation and 
nuclear pleomorphism) and the proliferative activity (mitotic index) of a tumor. High-grade 
breast cancers tend to recur and metastasize early while patients with low-grade tumors 
generally have a very good clinical outcome. However, many breast cancers fell into the 
intermediate grade category that is very heterogeneous with varying prognosis. 
Incorporation of tumor stage allows a more accurate prediction of patient prognosis 
and has led to the development of the Nottingham Prognostic Index (Galea et al., 1992). The 
staging system for breast cancer is based on the TNM (Tumor, Node, Metastasis)-
classification and reflects the extent of spread of the cancer when it is first diagnosed. The 
TNM staging takes into account the size of the tumor (T), the lymph node involvement (N) 
and the presence or absence of distant metastases (spread to distant organs) (M). Once the 
T, N and M are determined, a stage of 0, I, II, III, or IV is assigned, with stage 0 being in situ, 
stage I being early stage invasive cancer, and stage IV being the most advanced. In general, 
TNM stage is inversely correlated with the prognosis. 
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Immunohistochemical (IHC) biomarkers such as the expression of estrogen receptor 
(ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2) 
provide additional therapeutic predictive value. In general, ER expression is associated with 
a favorable prognosis and response to endocrine therapy while HER2 amplification suggests 
aggressive behavior and response to anti-Her2 therapy (trastuzumab) (National Institutes of 
Health Consensus Development, 2001). Therefore, the current approach incorporates IHC 
biomarkers with tumor grade, tumor stage, presence of extensive vascular invasion and 
patient's age. Most of these variables are combined in Adjuvant! Online 
(www.adjuvantonline.com), a free web-based tool that predicts breast cancer outcomes and 
the efficacy of adjuvant therapy in patients with breast cancer. 
However, although the existing classification has been fundamental for prognostic and 
predictive evaluation in groups of patients, its role in evaluating risk in an individual patient 
with breast cancer is more limited, as tumors with apparent similarities in clinical and 
pathological characteristics may have different responses to therapy and clinical outcomes. 
This inaccuracy leads to overtreatment of some patients with unnecessarily toxic therapies 
and to undertreatment of others who receive false assurance of a favorable prognosis 
(Bergh and Holmquist, 2001). In addition, this classification provides limited insight into the 
complex underlying biology and the molecular pathways driving the disease in different 
subtypes. As a result, a molecular classification of breast cancers based on their gene 
expression profile has been proposed in recent years. 
2.2. Molecular classification: intrinsic subtypes 
Gene expression profiling using microarray technology allows simultaneous 
measurement of the expression of thousands of genes in a single tissue sample and 
represents a valuable tool to assess molecular and potential biological differences in breast 
cancers. Using this technology, Perou, Sorlie and colleagues (Perou et al., 2000; Sorlie et al., 
2001) demonstrated the stratification of breast tumors into several major subtypes beyond 
the traditional hormone receptor-positive and hormone receptor-negative subgroups. The 
most reproducibly identified molecular subtypes among the hormone receptor-positive 
tumors are the luminal A and luminal B groups. The HER2 and basal-like groups are the 
major molecular subtypes identified among hormone receptor-negative tumors. Other 
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molecular subtypes such as luminal C and normal breast-like groups have also been 
identified in some studies, but are less well characterized than the luminal A, luminal B, 
HER2, and basal-like types. These breast cancer molecular subtypes not only have distinct 
gene expression profiles, but also have unique clinical features, prognosis and response to 
therapy, as summarized in Table 1 (Schnitt, 2010). 
Table 1. Clinical and pathological features of major molecular subtypes of breast cancer determined 
by gene expression profiling (adapted from Schnitt, 2010). 
 
 
Luminal A subclass are mostly ER-positive low-grade tumors characterized by a high 
expression level of luminal cytokeratins (CKs 8/18/19), ER, PR, BCL2 and P27KIP1, and a low 
expression of TP53 and HER2. Luminal B subtype share many of these characteristics but 
tend to have higher grade and lower expression of hormone receptors and may overexpress 
HER2. Basal-like tumors are high grade ER- and PR-negative tumors with low levels of 
luminal CKs, BCL2, P27 and HER2, and a high expression of basal CKs 5/6/14/17, TP53 and 
epidermal growth factor receptor (EGFR). HER2 tumors are more likely to be high grade and 
are characterized by a low, if any, expression level of ER, PR and P53 and a high expression 
of HER2. 
The different gene expression patterns observed in breast tumors reflect their biological 
diversity and are associated with distinct prognosis (Figure 4) (Sorlie et al., 2001; Sorlie et 
al., 2003). An important finding is the separation of ER-positive tumors into at least two 
distinctive groups with a different disease course: luminal A with the best prognosis and 
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luminal B with a worse outcome, in particular with respect to relapse. Basal-like and HER2 
tumors have the worst prognosis, presenting the shortest overall survival and relapse-free 
survival.  
 
Figure 4. Kaplan–Meier analysis of disease outcome in breast cancer patients stratified according to 
the intrinsic subtypes. A) Time to development of distant metastasis in 97 sporadic cases. B) Overall 
survival for 72 patients with locally advanced breast cancer (adapted from Sorlie et al., 2003).  
 
Molecular subtypes have also proved to have significant predictive value for therapeutic 
response of breast cancer. Table 2 summarizes the treatment recommendations adopted by 
the 13th St Gallen International Breast Cancer Conference (2013) Expert Panel (Goldhirsch 
et al., 2013). Luminal cancers are generally hormone receptor-positive and appropriate for 
endocrine therapy. Luminal A subtype is less responsive to chemotherapy than luminal B 
tumors and therefore chemotherapy is not usually recommended for this subgroup of 
patients. HER2 positive tumors are suitable for targeted therapy such as trastuzumab with 
great clinical success. Chemotherapy is also appropriate for this group except for patients at 
very low risk. Basal-like subtype is resistant to current targeted therapies for breast cancer 
but benefits from chemotherapy much more than ER-positive tumors (Colleoni et al., 2000). 
Table 2. 2013 St Gallen consensus definition of intrinsic subtypes of breast cancer and 
recommendations of systemic treatment (adapted from Goldhirsch et al., 2013). 
Intrinsic subtype IHC definition Type of adjuvant therapy 
Luminal A ER+,PR+,HER2-,Ki67low Endocrine therapy alone* 
Luminal B ER+,HER2-,Ki67high/PRlow Endocrine + cytotoxic therapy 
Luminal B ER+,HER2+,anyKi67,anyPR Endocrine + cytotoxics + anti-HER2 therapy 
HER2 ER-,PR-,HER2+ Cytotoxics + anti-HER2 therapy 
Basal-like ER-,PR-,HER2- Cytotoxic therapy 
*Cytotoxics may be added in patients at high risk (high 21-gene RS, high 70-gene RS, grade 3, high 
nodal status) 
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2.3. Surrogate classifications 
The main problem of the original molecular classification is that it has been derived from 
investigations on fresh frozen tissue, and it is not applicable to formalin-fixed and paraffin-
embedded (FFPE) material, limiting its use in the clinical practice. More recently, a gene 
expression assay using 50 genes (PAM50) has been developed for use on FFPE tissue (Parker 
et al., 2009). The assay is based on quantitative real-time reverse transcription-polymerase 
chain reaction (qRT-PCR) of genes involved in proliferation, ER and ER-regulated genes, 
HER2, and basal and myoepithelial characteristics. The predictor accurately identifies the 
major molecular subtypes of breast cancer and generates risk-of-relapse (ROR) scores. The 
ability of the ROR score to predict prognosis has been confirmed in several retrospective 
investigations using tumor samples of patients with long-term follow-up data and of 
patients enrolled in randomized, clinical trials (Ellis et al., 2011; Nielsen et al., 2010). The 
PAM50 test is currently being developed for clinical use on the NanoString nCounter 
Analysis System (Prosigna™ Breast Cancer Gene Signature Assay, NanoString Technologies, 
Seattle) (Geiss et al., 2008; Reis et al., 2011). 
Another attempt to bring the molecular classification of breast cancer into the clinical 
practice has been the use of the more familiar immunohistochemical markers. Accordingly, 
the combined evaluation of ER, PR, HER2 and Ki67 immunoreactivity would approximate the 
molecular classification of luminal A, luminal B, HER2-enriched and basal-like breast cancers. 
In fact, the panelists of the last St. Gallen Conference have endorsed the use of this markers 
to identify breast cancer subtypes and to inform the choice of the systemic treatments 
(Table 2) (Goldhirsch et al., 2013). However, recent studies have indicated that other 
markers in addition to ER, PR, HER2 and Ki67 are required to more accurately approximate 
the molecular subtypes. As an example, some basal-like breast cancers will not show the 
expected triple negative (ER, PR and HER2 negative) immunophenotype, and vice versa not 
all the immunohistochemically triple negative breast cancer will be classified as basal-like by 
gene expression profiling (Carey et al., 2010). The basal-like group can be defined more 
precisely using, in addition to ER, PR, and HER2, antibodies to CK5/6 and EGFR as basal-like 
cancers are most often triple negative and also express CK5/6 and/or EGFR. IHC-based 
definition of luminal A and luminal B breast tumors is also imperfect when compared with 
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gene expression profiling. As a result, a cut-point of >20% for PR has been proposed to 
define luminal A subtype (Prat et al., 2013).    
2.4. Triple negative breast cancer: a clinical challenge 
Triple negative breast cancers are defined as tumors that lack ER and PR expression and 
HER2 overexpression. These tumors represent an important clinical challenge because they 
do not respond to current targeted therapies for breast cancer, being chemotherapy the 
only option for triple negative patients. Moreover, these tumors are associated with the 
most aggressive clinical behavior and poorest prognosis in breast cancer. 
Around 15% of invasive breast cancers are triple negative tumors. Even though there is 
considerable overlap between the profiles of triple negative and basal-like tumors, not all 
basal-like cancers determined by gene expression profiling lack ER, PR and HER2, and 
conversely, not all triple negative breast cancers express basal markers at the protein level. 
It is estimated that nearby 80% of basal-like cancers are triple negative and around 70% of 
triple negative tumors show a basal-like phenotype. The remainder 30% of triple negative 
tumors consists of a variety of molecular subtypes that are biologically distinct (Badve et al., 
2011). In addition to this molecular heterogeneity, there is a histologic diversity. Although 
most of triple negative cancers are invasive carcinomas of no special type, other rare types 
are also included, ranging from those with an excellent prognosis to aggressive metaplastic 
carcinomas. Therefore, there is a clinical need to identify prognostic and predictive markers 
to substratify patients with triple negative cancers into groups that can be managed more 
efficaciously with specific therapies.  
2.4.1. Similarities with basal-like breast cancers 
Due to their large overlap, triple negative tumors show many characteristics that are 
associated with basal-like cancers. Typically they are grade 3 carcinomas with elevated 
mitotic count, high apoptotic rate, geographic or central tumor necrosis or fibrosis, a 
pushing border of invasion and a stromal lymphocytic response. In addition to the lack of 
expression of ER, PR and HER2, they frequently express basal cytokeratins (particularly CKs 
5, 14 and 17) and the EGFR (Her1). Compared with other subtypes, they are more likely to 
express myoepithelial markers, such as caveolins, c-kit and P-cadherin, and less likely to 
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express epitelial markers, such as e-cadherin. They also have high expression of genes 
associated with proliferation (Ki67 and TOP2A) and up to 70% of them show TP53 gene 
mutations and/or nuclear accumulation. Expression of p53 homolog p63 is also upregulated 
(Carey et al., 2010). 
Triple negative and basal-like cancers occur more frequently in younger patients (<50 
years old) and generally behave aggressively. Women of African ancestry have been shown 
to have higher rates of triple negative disease, probably due to mutations that predispose to 
this subtype. The pattern of spread of tumors with a basal-like phenotype is different from 
that of other subtypes: while luminal tumors typically cause late bone metastases, triple 
negative breast cancer is more likely to cause early visceral metastases, fundamentally in 
brain and lungs. In addition, triple negative breast cancers are associated with a higher 
recurrence rate after diagnosis, a shorter disease-free interval, a shorter period from the 
time of recurrence until death and a shorter overall survival. The peak risk of recurrence is 
between the first and third years and the majority of deaths occur in the first 5 years 
following therapy (Dent et al., 2007). 
2.4.2. Triple negative breast cancer and the BRCA1 pathway  
There is increasing evidence to suggest a link between BRCA1 pathway and triple 
negative breast cancers. The majority of tumors in BRCA1 mutation carriers are triple 
negative and show morphological and immunohistochemical similarities to basal-like 
cancers. Both triple negative and BRCA1-mutated tumors are characterized by high 
histological grade, atypically medullary features, high proliferation indices, pushing borders 
and lymphocytic infiltrate. Both lack ER, PR and HER2 expression and show p53 
immunoexpression and TP53 somatic mutations, EGFR expression, peculiar patterns of cell-
cycle protein expression and characteristic copy number aberrations. All this characteristics 
has led to the definition of the BRCAness phenotype (Turner and Reis-Filho, 2006). 
Moreover, it has been shown that BRCA1-mutated tumors consistently segregate with 
sporadic basal-like breast cancers in hierarchical clustering analysis using microarray 
expression profiling data. By contrast, tumors from BRCA2 mutation carriers are 
predominantly hormone receptor positive and show similar gene expression profiles to 
sporadic luminal cancers (Sorlie et al., 2003). 
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Even though BRCA1 somatic mutations have not been identified in sporadic triple 
negative tumors, a reduced expression of the BRCA1 gene has been observed in most of the 
cases, which indicates a central role of BRCA1 in the development of basal-like carcinomas. 
This low expression has been associated with BRCA1 promoter hypermethylation, loss of 
heterozygosity (LOH) at the BRCA1 locus and overexpression of two proteins: HMGA1 and 
ID4 (Mueller and Roskelley, 2003; Turner et al., 2007). Nevertheless, it seems that other 
mechanisms might also be involved in the inactivation of BRCA1 in sporadic triple negative 
tumors as those already described cannot account for the entire reduction of BRCA1 in 
these tumors. 
2.4.3. Treatment strategies 
Given the lack of hormone receptors and HER2 overexpression, chemotherapy is the 
only possibility for patients with triple negative disease. Regimens based on anthracyclines 
or taxanes are effective with high in-breast response rates. However, relapse rates are high 
in patients who do not achieve a pathologic complete response, resulting in a short disease-
free survival and overall survival. Hence, other agents such as EGFR inhibitors, Src inhibitors, 
anti-angiogenic agents (Bevacizumab), androgen receptor targeted agents, poly(ADP-ribose) 
polymerase (PARP) inhibitors and platinum salts are currently being evaluated. In particular, 
platinum compounds and PARP inhibitors are effective in tumors with a dysfunctional 
BRCA1 pathway (Hudis and Gianni, 2011). The ongoing trials will show if these agents are 
more effective than conventional therapy and whether they are able to improve outcomes 
in this poor-prognosis group of patients.  
2.5. Gene expression predictors of breast cancer outcomes 
During the last decade, several gene signatures have been described for predicting 
outcome in patients with breast cancer. Two of them, Oncotype DX (Paik et al., 2004) and 
Mammaprint (Glas et al., 2006), have been validated with consistent results across multiple 
studies and have been shown to provide independent prognostic information beyond 
standard clinicopathological variables. These predictors have been endorsed by the 2013 St 
Gallen International Breast Cancer Expert Panel (Goldhirsch et al., 2013) and are the most 
widely used clinical gene-expression assays. 
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Oncotype is a 21-gene signature generated to predict prognosis of node-negative 
patients treated with tamoxifen. This assay uses qRT-PCR to measure the expression of 5 
reference genes and 16 genes of interest related to proliferation, HER2 and ER signalling. 
The resulting recurrence score (RS) is 0 to 100, which translates into three risk-group 
categories: low (RS <18), intermediate (RS from 18 to <31) and high (RS ≥31). An interesting 
feature of this test is the fact that frozen tissues are not needed since the score is generated 
using RNA from FFPE tumors. Oncotype has been approved to identify a subgroup of 
patients within the ER-positive, node-negative breast cancer group who would benefit from 
addition of chemotherapy and more importantly to identify patients who could possibly be 
spared cytotoxic therapy. Currently, the RS is undergoing prospective validation as part of 
the Trial Assigning Individualized Options for Treatment (TAILORx) trial in order to establish 
if adjuvant chemotherapy improves survival in the group of patients with the intermediate 
score (Sparano and Paik, 2008).  
Mammaprint is a 70-gene signature established to predict outcome in node-negative 
patients irrespective of ER status. The assay is based on a microarray platform that 
measures the expression of 70 genes associated with proliferation, invasion and 
angiogenesis. Initially the test could only be performed on fresh tumor (rarely available), but 
improvements in RNA processing have enabled its use in FFPE tissue. MammaPrint divides 
node-negative patients in two groups of low and high risk of recurrence. Currently this assay 
is undergoing prospective validation as part of the Microarray for Node-Negative Disease 
Avoids Chemotherapy (MINDACT) trial in order to establish if lymph node–negative breast 
cancer patients with low risk of recurrence according to Mammaprint but at high risk of 
recurrence based on clinicopathological factors can be safely spared adjuvant chemotherapy 
without affecting survival outcomes (Cardoso et al., 2008). 
Although promising, these gene expression assays assign almost all patients with 
hormone receptor negative disease as high risk. They have been shown to made robust 
prognostic predictions within the group of ER-positive patients but not within the ER-
negative disease (Fan et al., 2011). Hence, other signatures able to predict survival within 
the HER2-positive and triple negative cancers are urgently needed. 
52 
 
2.6. New technologies and novel subgroups 
A new breast cancer subtype, known as claudin-low, has been identified in human 
tumors, in mouse tumors (Herschkowitz et al., 2007) and in a panel of breast cancer cell 
lines (Prat et al., 2010). These tumors are poor prognosis ER-, PR- and HER2- invasive ductal 
carcionomas characterized by low expression of genes involved in tight junctions and cell-
cell adhesions including claudins 3, 4, and 7, occludin and E cadherin, showing high 
expression of epitelial to mesenchymal transition genes and stem cell features. As a 
consequence of the identification of this novel subgroup, triple negative breast cancers 
would be further subdivided into basal-like and claudin-low tumors.   
More recently, the emergence of next generation sequencing has allowed the 
characterization of the mutational landscape of breast cancer. These analysis have identified 
likely genomic drivers of the four classical subtypes by focusing on the detection of genes 
more frequently mutated than expected by chance (Banerji et al., 2012; Stephens et al., 
2012; The Cancer Genome Atlas, 2012). Somatic mutations in only three genes (TP53, 
PIK3CA and GATA3) have been shown to occur at >10% incidence across all breast cancers, 
although their frequency is different among the intrinsic subtypes. 
The same technology has been used in the Molecular Taxonomy of Breast Cancer 
International Consortium (METABRICK) study in which the integrated analysis of both 
genomic and transcriptomic data across 2000 breast tumors has revealed ten different 
subtypes of breast cancer (Curtis et al., 2012a). In this analysis, germline variants and 
somatic aberrations were found to be associated with alterations in gene expression, 
although somatic copy number alterations accounted for the greatest variability in gene 
expression. Unsupervised analysis of joint copy number and gene expression data revealed 
ten novel subgroups with distinct clinical outcomes and patterns of chemosensitivity 
(IntClust 1-10). This genome-driven integrated classification has just been simplified into a 
gene-expression based method that has been validated in 7500 breast tumors (Ali et al., 
2014). The clinical relevance of the IntClust classification and its implications for the 
development of new targeted therapies will be disclosed in the next years. 
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3. MICRORNAs AS MASTER GENE REGULATORS  
3.1. MicroRNA biogenesis and function 
MicroRNAs (miRNA) are small (~22 nucleotides) single-stranded non-coding RNAs that 
have an important function in gene expression regulation. After the discovery of the first 
miRNA lin-4 in Caenorhabditis elegans in 1993 (Lee et al., 1993), these small RNAs have 
been found to be an abundant class of RNAs in plants, animals and DNA viruses. MiRNAs act 
as negative regulators at post-transcriptional level by binding at the 3’ untranslated regions 
(3’UTRs) of their target messenger RNAs (mRNAs). Depending on the level of 
complementarity between miRNA “seed” sequence and its target, they trigger either 
translational repression or mRNA degradation (Bartel, 2009). The exact mechanisms of 
miRNA function are still far from being fully understood and are a matter of active research. 
With more than 2500 reported human miRNAs (miRBase 21.0 release, June 2014), and each 
one potentially regulating hundreds of mRNAs, miRNAs represent one of the largest classes 
of gene regulators. Since many of these miRNA targets are involved in various signaling 
pathways, their impact on gene expression can be significantly amplified. In addition, many 
miRNAs are evolutionarily conserved from worms to humans, which implies that they are 
essential both during development and in the adult body. MiRNAs can function as master 
gene regulators, play an important role in many cellular processes such as differentiation, 
proliferation, apoptosis and stress response, and their alteration contributes to a range of 
human diseases, including cancer. 
The biogenesis of miRNAs involves a complex protein system (Figure 5). MiRNAs, which 
generally seem to be transcribed by RNA polymerase II, are initially made as large RNA 
precursors that are called pri-miRNAs. The pri-miRNAs are processed in the nucleus by 
Drosha, a member of the RNase III enzyme family, in conjunction with the double-stranded 
RNA-binding protein Pasha, into ~70-nucleotide pre-miRNAs, which fold into imperfect 
stem-loop structures. After exported from the nucleus in a GTP-dependent fashion by 
exportin 5, the pre-miRNAs are subsequently processed by a second RNase III endonuclease 
called Dicer, releasing mature double-stranded miRNAs (~22 nucleotides in length), which in 
turn are incorporated into the RNA-induced silencing complex (RISC). One of the strands is 
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preferentially incorporated while the other is degraded giving rise to a functional RISC 
complex that can target specific protein-coding mRNAs (Esquela-Kerscher and Slack, 2006). 
 
Figure 5. MiRNA biogenesis and functions (adapted from Esquela-Kerscher and Slack, 2006). 
 
3.2. Alteration of miRNA expression in cancer 
MiRNAs have been proposed to have a central role in controlling cellular transformation 
and tumor progression since they can function as tumor suppresors and oncogenes 
(oncomiRs). The downregulation or deletion of a miRNA that targets an oncogene leads to 
tumor formation, and vice versa, the amplification or overexpression of a miRNA that 
targets a tumor suppressor results in tumorigenesis (Esquela-Kerscher and Slack, 2006). 
MiRNA genes are usually located in small chromosomal alterations in tumors (in 
amplifications, deletions or linked to regions of loss of heterozygosity) or in common 
chromosomal-breakpoints that are associated with the development of cancer (Calin et al., 
2004). In addition to structural genetic alterations, miRNAs can also be silenced by promoter 
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DNA methylation, loss of histone acetylation and abnormalities in miRNA-processing genes 
and proteins. Somatic mutations in miRNA seed sequence could lead to lack of repression of 
oncogenic mRNAs and/or aberrant downregulation of tumor supressive genes, but these 
seem to be infrequent (Diederichs and Haber, 2006). 
Cancer cells show alterations in their miRNA expression profiles, and emerging data 
indicate that these patterns could be useful in improving the classification of cancers and 
predicting their behaviour. The first evidence of involvement of miRNAs in human cancer 
came from molecular studies characterizing the 13q14 deletion in human chronic 
lymphocytic leukemia (CLL). Two miRNAs, miR-15a and miR-16-1, located within this región 
were identified to be either deleted or downregulated in >50% CLL (Calin et al., 2002). 
Further studies have shown that miR-15a and miR-16-1 negatively regulate BCL2, an anti-
apoptotic gene that is often overexpressed in many cancers, including leukaemias and 
lymphomas (Cimmino et al., 2005). Following this initial discovery, abnormal expression of 
miRNAs has been found in both solid and hematopoietic tumors by various genome-wide 
miRNA expression analysis techniques (Lu et al., 2005; Volinia et al., 2006). Cancer cells 
show distinct miRNA profiles compared with normal cells, and different miRNA expression 
profiles have been reported in tumors of different origin. Indeed, miRNA expression 
profiling seems to be a more accurate way of classifying tumors than gene expression 
profiling (Lu et al., 2005). Furthermore, miRNAs have one great practical advantage over 
mRNA: they are relatively well preserved in FFPE tissues presumably due to their small size 
and possibly a sheltered micro-environment (Hasemeier et al., 2008). 
3.3. MiRNAs in breast cancer 
Accumulating evidence demonstrates that aberrant expression of miRNAs is associated 
with breast cancer. The seminal study of miRNA expression in 76 breast tumors and 10 
normal breast tissues led to the identification of 29 miRNAs whose expression is significantly 
dysregulated in breast cancer with the most consistently dysregulated miRNAs being miR-
125b, miR-145, miR-10b, miR-21 and miR-155. Mir-10b, miR-125b and miR-145 were found 
to be downregulated, whereas miR-21 and miR-155 were upregulated, suggesting that they 
may potentially act as tumor suppressor genes or oncogenes, respectively (Iorio et al., 
2005). Follow-up studies based on different technologies have validated some of these 
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miRNAs and identified new ones, suggesting reproducibility of miRNA deregulation in breast 
cancer (Farazi et al., 2011; Persson et al., 2011; Sempere et al., 2007; Volinia et al., 2006; 
Volinia et al., 2012). Since the number of annotated miRNAs increases every year, new 
miRNAs are still expected to be asociated with breast cancer.  
In addition, some studies have correlated miRNA expression with specific breast cancer 
histopathological features such as tumor stage, proliferation index, vascular invasion, ER, PR 
and HER2 status (Iorio et al., 2005; Lowery et al., 2009; Mattie et al., 2006; Volinia et al., 
2012). Furthermore, preliminary studies suggest that miRNA signatures could define, 
similarly to what has been found by expression profiling of coding genes, the different 
intrinsic molecular subtypes (luminal A, luminal B, basal-like, HER2+). By analyzing the 
expression of 309 human miRNAs, Blenkiron and colleagues detected a number of miRNAs 
differentially expressed between these molecular subtypes (Blenkiron et al., 2007). 
Identification of miRNAs specific of breast cancer molecular subtypes would be of great 
relevance due to their potential influence on the different behavior of these tumors. 
Subtype-specific miRNAs could be used for classification purposes, as well as to provide 
better understanding of the biology of these groups of tumors, especially in the case of 
triple negative cancers, which are associated with the most aggressive clinical behavior and 
poorest prognosis in breast cancer and do not respond to current targeted therapies.  
3.4. Circulating miRNAs as novel non-invasive biomarkers 
Perhaps the most attractive application of miRNAs as cancer biomarkers comes from the 
finding of circulating miRNAs in different body fluids such as plasma, serum, urine, saliva, 
milk, etc. Tumor-specific miRNAs were first discovered in the serum of patients with diffuse 
large B-cell lymphoma (Lawrie et al., 2008). Since then, circulating miRNAs are attracting a 
great deal of attention as novel cancer biomarkers due to their ease of access and 
remarkable stability. It has been consistently shown that circulating miRNAs remain stable 
after being subjected to severe conditions that would normally degrade most RNAs, such as 
boiling, very low or high pH levels, extended storage, and 10 freeze–thaw cycles (Chen et al., 
2008). This stability can be partially explained by two mechanisms: (i) protection of secreted 
miRNAs by the membrane of vesicles of endocytic origin called exosomes or microvesicles 
(30–100 nm) (Valadi et al., 2007), and (ii) stabilization of secreted miRNAs by their 
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association with RNA-binding proteins, such as AGO2 and NPM1 (Arroyo et al., 2011). 
Importantly, exosomes represent a newly discovered mechanism by which donor cells can 
communicate and influence the gene expression of recipient cells (Valadi et al., 2007), and 
studies have shown that tumor-derived exosomes can promote tumor progression (Skog et 
al., 2008). Although it is unclear how circulating miRNAs are liberated into body fluids, the 
packaging of specific miRNA populations into microvesicles appears to be a selective 
process. Studies in malignant mammary epitelial cells have demonstrated that the cellular 
and the extracellular miRNA profiles are different, suggesting that specific miRNAs are 
selected to be intracellularly retained or released by exosomes (Pigati et al., 2010). In 
addition, it seems that certain circulating miRNAs could be differentially expressed in the 
serum and plasma of breast cancer patients when compared with healthy individuals (Asaga 
et al., 2011; Cuk et al., 2013; Chan et al., 2013; Roth et al., 2010), indicating that these 
molecules may reflect the presence of a tumor. Nevertheless, few studies have been 
conducted in this area and further research is required.  
In summary, the findings discussed above highlight the potential clinical utility of 
circulating miRNAs in breast cancer diagnosis. Studies in large cohort of patients with well-
defined clinical data are needed in order to identify circulating miRNAs that could 
discriminate breast cancer patients from healthy individuals with robustness and 
reproducibility. In addition, their analysis in treated patients will shed light on their 
correlation with tumor dynamics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Objectives 
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A large number of studies have explored the value of gene expression profiling in breast 
cancer, thus leading to some very interesting findings that have been successfully translated 
to the clinic. However, few reports have investigated the usefulness of miRNA expression 
profiling in breast cancer diagnosis, prognosis and treatment. Given the important role that 
miRNAs play in tumorigenesis and their great potential as novel clinical biomarkers, the 
specific goals of this thesis were: 
 
1. To identify miRNAs differentially expressed in breast tumors and the main molecular 
subtypes of breast cancer (luminal A, luminal B, Her2 and triple negative) and to 
establish miRNA signatures for their discrimination. 
 
2. To study in plasma the status of the most deregulated miRNAs identified in breast 
tumors and to analyze their utility as non-invasive biomarkers for early breast 
cancer detection. 
 
3. To identify prognostic and/or predictive miRNAs in triple negative breast cancer 
patients. 
 
4. To investigate the involvement of miRNAs in BRCA1 regulation in sporadic triple 
negative breast cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and methods 
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1. PATIENTS AND SAMPLES 
1.1. Types of samples and ethics statement 
Samples used in this thesis were collected from breast cancer patients and healthy 
women of the same ethnicity (white Spaniards) in five Spanish institutions: Hospital Virgen 
de la Macarena and Hospital Virgen del Rocío (Sevilla), Hospital Monte Naranco and 
Biobanco del Principado de Asturias (Oviedo) and Sistemas Genómicos (Valencia). Two 
different types of samples were obtained:  
Formalin-fixed paraffin embedded (FFPE) breast tumors were obtained from patients 
undergoing surgery for breast cancer. In addition, normal breast tissues were acquired after 
breast reduction surgery from healthy women with no family history of cancer and were 
used as control samples. FFPE tissues were stained by hematoxylin and eosin and examined 
by two pathologists (Ricardo González-Cámpora and Primitiva Menéndez). The tumoral area 
was identified and macrodissected from 3 sections of 30 μm thicknesses for subsequent 
RNA extraction. 
Plasma samples were collected from breast cancer patients and healthy women. 
Plasma from breast cancer patients were divided into two groups: those obtained at the 
time-point of diagnosis before any treatment such as surgery, radiation or systemic therapy 
(pretreated) and those obtained after treatment (postreated). EDTA blood samples were 
processed for plasma within 1 hour of collection. Blood was centrifuged at 3000 g for 20 
minutes at 10ºC followed by further centrifugation of the supernatant at 15500 g for 10 
minutes at 10ºC to remove cell debris. The plasma was stored at -80ºC until use.  
The study was performed in accordance with the principles of the Declaration of 
Helsinki. Written informed consent was obtained from all patients prior to sample 
collection, and the study was approved by the ethics committee of Instituto de Salud Carlos 
III (Madrid), Hospital Virgen del Rocío and Virgen de la Macarena (Sevilla) and Hospital 
Monte Naranco (Oviedo). 
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1.2. Patients’ clinical data 
Clinicopathologic features (age at diagnosis, histological type, tumor size, histologic 
grade, lymph node status, stage and expression of ER, PR, c-erb B2 and Ki-67) were retrieved 
from all patients. Tumors were classified as triple negative, Her2, luminal B or luminal A 
based on the expression of inmunohistochemical markers (ER, PR, c-erb B2 and Ki-67), 
following the criteria adopted in the 12th St Gallen International Breast Cancer Conference, 
2011 (Goldhirsch et al., 2011) and the definition of luminal A tumors proposed by Prat et al. 
(Prat et al., 2013). A summary of these criteria is shown in table 3. In the case of a weak 
positive reaction of c-erb B2, fluorescent in situ hybridization was performed to confirm the 
overexpression of this receptor. 
Table 3. Criteria used in this thesis to classify breast tumors into the main 
molecular subtypes. 
Molecular subtype IHC definition 
Luminal A ER+, PR high (≥20%), HER2-, Ki67 low (≤14%) 
Luminal B ER+, HER2-, Ki67 high (>14%) or PR low (<20%) 
 ER+, HER2+, any Ki67, any PR 
HER2 ER-, PR-, HER2+ 
Triple negative ER-, PR-, HER2- 
 
In addition, follow-up information was obtained from triple negative patients with the 
objective of performing survival analysis. Relapse-free survival (RFS) was defined as the time 
between initial diagnosis and relapse or death by the disease, with observations censored at 
last follow-up if no event had occurred. Median follow-up time of patients alive was 62 
months (range: 57–99 months). Patients had not been treated with any systemic 
neoadjuvant therapy and had received adjuvant chemotherapy consisting in most cases in 
taxanes and/or anthracyclines. 
1.3. Samples cohorts 
During the elaboration of this thesis four different studies were performed including 
variable number of samples.  
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First study: one hundred and twenty-two FFPE breast tumors, as well as 11 normal 
breast tissues, were used for microarray profiling. Breast tumors were divided into a training 
(n=61) and a test set (n=61). Both series comprised a similar number of samples from each 
molecular subtype. 
Second study: plasma samples were collected from 83 breast cancer patients and 26 
healthy women for study of selected miRNAs in blood. Plasma from breast cancer patients 
were divided into two groups: those obtained at the time-point of diagnosis before any 
treatment (n=36) and those obtained after treatment (n=47). In addition, a validation set of 
plasma samples from 114 pretreated breast cancer patients and 116 healthy women was 
obtained. 
Third study: twenty-one FFPE breast tumors from triple negative patients included in 
the first study were used here for survival analysis. A second series of 22 TN FFPE tumors 
was obtained for validation of selected miRNAs.  
Fourth study: a panel of 6 human cell lines was used as a model to study functional 
effects of miRNA expression and inhibition. Five of them (MDA-MB-231, Hs578T, SKBR3, 
BT474 and MCF7) corresponded to sporadic breast tumors and were representative of the 
main molecular subtypes of breast cancer, and one (HEK-293T) was derived from an 
embryonic kidney. 
2. RNA EXPRESSION ANALYSIS 
2.1. RNA extraction and quantification 
Total RNA was extracted from FFPE tissues using miRNeasy FFPE Kit (Qiagen, Valencia, 
CA, USA) according to the manufacturer’s instructions. RNA from plasma was extracted from 
250 ml of plasma using miRNeasy Mini Kit (Qiagen, Valencia, CA, USA) and the modified 
Exiqon protocol that includes the addition of MS2 RNA (Roche, Basel, Switzerland), a carrier 
RNA that ensures the highest and most consistent yield of RNA in the samples. The final 
elution volume was 50 μl. Finally, RNA from cell lines was extracted using miRNeasy Mini Kit 
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(Qiagen) according to the manufacturer’s instructions. RNA quality and quantity were 
assessed by NanoDrop Spectophotometer (NanoDrop technologies, Wilmington, DE, USA). 
2.2. Microarray hybridization 
MicroRNA expression profiling was performed using miRCURY LNATM microRNA Array 
7th generation – hsa, mmu & rno (Exiqon A/S, Vedbaek, Denmark), in a single-color 
experimental design. The miRCURY LNATM microRNA Array 7th generation – hsa, mmu & rno 
contains capture probes for all microRNAs in human, mouse, rat and their related viruses as 
annotated in miRBase Release v.18.0. This includes probes for 1919 human miRNAs in 
quadruplicate: 1894 miRNAs from miRBase Release 18.0 and 25 hsa-miRPlus not included in 
miRBase (Exiqon proprietary). In addition, 82 control probes are included: 52 spike-in 
control probes to ensure optimal labeling and hybridization, 7 negative control probes and 
23 probes complementary to small nuclear RNAs. 
Labeling and hybridization procedure was performed as recommended by 
manufacturer, using miRCURY LNA™ microRNA Hi-Power Labeling Kit (Exiqon). First, 300ng 
of total RNA was treated with Calf Intestinal Alkaline Phosphatase (CIP) to remove the 5’-
phosphates from the microRNA termini. The 5 ul –reaction contained 0.5 ul of CIP buffer, 
0.5 ul of CIP enzyme, 1 ul of synthetic RNA spike-in and 3 ul of RNA. The reaction was 
incubated at 37ºC for 30 min and 95ºC for 5 min. Second, a Hy3 fluorescent label was 
attached enzymatically to the 3’-end of the microRNAs in the total RNA sample. The 12.5 ul -
reaction contained 3 ul of labeling buffer, 1 ul of labeling enzyme, 1.5 ul of Hy3 fluorescent 
dye, 2 ul of DMSO and 5 ul of CIP treated RNA. The reaction was incubated at 16ºC for 1h 
and heat inactivated by incubation at 65ºC for 15 minutes. Third, labeled samples were 
combined with 200 ul of hybridization buffer, denatured at 95ºC for 2 min and loaded onto 
a miRCURY LNA™ microRNA array slide. Hybridization took place over 16h at 56ºC using 
Agilent Hybridization chambers SureHyb and a rotating oven.  
Arrays were then washed, dried and scanned with Agilent G2565AA Microarray Scanner 
System (Agilent Technologies, Santa Clara, CA, USA), with the laser set to 635nm, at Power 
80 and PMT 70 setting, and a scan resolution of 10μm. To avoid ozone bleaching, 
microarrays were scanned in an ozone-free environment (less than 2 ppb ozone). 
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Fluorescence intensities on scanned images were measured with Agilent Feature Extraction 
software, version 10.7.3 (Agilent Technologies), using the modified Exiqon protocol. 
Reproducibility and reliability of each single microarray was assessed using Quality Control 
report data. Microarray dataset is publically available at NCBI’s Gene Expression Omnibus 
database http://www.ncbi.nlm.nih.gov/geo/ under GEO accession number GSE58606.  
2.3. Microarray data analysis  
2.3.1.  Normalization and pre-processing 
Microarray background subtraction was carried out using normexp method. Processed 
intensity data were then log2 transformed and normalized using quantiles between arrays 
normalization. Replicate probes were merged by their mean profile and the data set was 
filtered to eliminate miRNAs with low expression variation across samples (VAR<0.03), 
reducing the number of miRNAs to 698.  
2.3.2. Clustering 
In order to obtain clustering of the data, unsupervised hierarchical clustering was 
performed using Gene Cluster software with average linkage clustering, Pearson correlation 
and uncentered metrics (http://rana.stanford.edu/software). Java Tree View was used for 
image visualization (http://jtreeview.sourceforge.net). The level of expression of each 
miRNA in each sample, relative to the median level of expression of that gene across all the 
samples was represented using a red-black-green color scale. Green corresponds to 
expression value below median, black equal to median, and red above the median.   
2.3.3. Differential expression analysis 
Differentially expressed miRNAs were obtained by applying linear models with R limma 
package (Smyth G) (Bioconductor project, http://www.bioconductor.org), implemented in 
the POMELOII tool (http://asterias.bioinfo.cnio.es/). To account for multiple hypotheses 
testing, the estimated significance level (p value) was adjusted using Benjamini & Hochberg 
False Discovery Rate (FDR) correction (Benjamini et al., 2001). FDR<0.05 was set as 
threshold to select significantly differentially expressed miRNAs. 
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2.3.4. Building miRNA microarray classifiers  
In order to identify the smallest set of miRNAs that better discriminate breast tumors 
from normal breast tissues, and each molecular subtype from the rest of subtypes, five 
miRNA microarray classifiers were generated using samples from the training set. The 
predictors were built with the 698 miRNAs used in the differential expression analysis and 
the most relevant miRNAs were chosen using correlation feature selection, a method that 
evaluates a set of features on the basis of the following hypothesis: "A good feature subset 
is one that contains features highly correlated with the class, yet uncorrelated with each 
other".  
We evaluated the performance of different methods that have been shown to function 
well with microarray data (Romualdi et al., 2003; Wessels et al., 2005): support vector 
machines (SVM), k-nearest neighbor (KNN) and random forest (RF), and that are included in 
the Prophet tool (http://babelomics.bioinfo.cipf.es/). These algorithms were applied to: i) 
61 breast tumors and 7 normal breast tissues, ii) 15 triple negative and 46 non-triple 
negative tumors, iii) 13 Her2 and 48 non-Her2 tumors, iv) 17 luminal B and 44 non-luminal B 
tumors, and v) 16 luminal A and 45 non-luminal A tumors. The classification performance 
was evaluated by 5-fold cross validation repeated 10 times: samples were randomly divided 
into 5 sets with each set containing a fair representation of the classes to be learned. A 
predictor was built based on the data of 4 of these sets and tested in the remaining set of 
samples to determine its efficiency. This process was repeated 10 times with different 
combinations of samples and average classification efficiency was determined. Classifiers 
producing the minimal root median square error (RMSE) and maximal accuracy, Mathews 
correlation coefficient (MCC) and area under the curve (AUC) were selected.  
To validate the performance of the selected classifiers, we used the samples from the 
test set: i) 61 breast tumors and 4 normal breast tissues, ii) 16 triple negative and 45 non-
triple negative tumors, iii) 13 Her2 and 48 non-Her2 tumors, iv) 16 luminal B and 45 non-
luminal B tumors, and v) 15 luminal A and 46 non-luminal A tumors. Sensitivity and 
specificity values were estimated based on the confusion matrix. 
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2.3.5. MiRNA target prediction 
A number of computational prediction programs have been developed to identify 
putative miRNA targets based on sequence complementarity between the miRNA and its 
potential mRNA target 3’ untranslated region (3’UTR) (Bartel, 2009). The most important 
factor for miRNA target prediction seems to be perfect complementarity to the 5’ region of 
the miRNA centered on nucleotides 2-8, which is called “miRNA seed” (Figure 6A). 
Furthermore pairing to the 3’ region of the miRNA can also compensate for a mismatch in 
the seed region. These so called “3’-compensatory sites” are centered on miRNA 
nucleotides 13-17 (Figure 6B). In an attempt to increase target prediction specificity some 
prediction algorithms are relying on target site evolutionary conservation and 
thermodynamic stability of the RNA-RNA duplex. To determine potential mRNA targets for 
specific miRNAs we have used several publically available target prediction algorithms, 
namely, TargetScan (http://www.targetscan.org/),  miRanda (http://www.microRNA.org/), 
Pita (http://genie.weizmann.ac.il/pubs/mir07/mir07_dyn_data.html), MicroTar 
(http://tiger.dbs.nus.edu.sg/microtar/), RNAHybrid (http://bibiserv.techfak.uni-
bielefeld.de/rnahybrid/) and DIANA microT (http://diana.imis.athena-
innovation.gr/DianaTools/index.php?r=microT_CDS/index). 
In addition, we have used a number of databases that compile experimentally validated 
miRNA-gene interactions, such as Diana TarBase (http://diana.imis.athena-
innovation.gr/DianaTools/index.php?r=tarbase/index), OncomirDB 
(http://bioinfo.au.tsinghua.edu.cn/member/jgu/oncomirdb/index.php), and miRecords 
(http://mirecords.biolead.org/). 
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Figure 6. Types of miRNA target sites. A) Canonical, 6-8 nt seed-matched sites. B) Atypical 3’ pairing. 
Vertical dashes indicate contiguous Watson-Crick pairing (adapted from Bartel, 2009). 
 
2.3.6. MiRNA pathway analysis 
DIANA miRPath pathway enrichment analysis (http://diana.imis.athena-
innovation.gr/DianaTools/index.php?r=mirpath/index) was used to gain insight into global 
molecular networks and canonical pathways related to deregulated miRNAs. DIANA 
miRPath is a web-based computational tool developed to identify molecular pathways 
potentially altered by the expression of single or multiple microRNAs. The software 
performs an enrichment analysis of multiple microRNA target genes (predicted or 
experimentally validated) comparing each set of microRNA targets to all known KEGG 
pathways. Those pathways showing p-value <0.05 were considered significantly enriched 
between classes under comparison.  
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2.4. Real time quantitative PCR (qRT-PCR) 
2.4.1. Detection of miRNA by qRT-PCR 
Quantification of the expression of the most relevant miRNAs was performed by qRT-
PCR using miRCURY LNATM Universal RT microRNA PCR system (Exiqon) according to the 
manufacturer’s protocol. In the case of FFPE tissues and cell lines, 12 ng of total RNA was 
reverse-transcribed with universal poly-T primers in 30 μl reactions. In the case of plasma 
samples and due to the low RNA concentrations, RNA amounts were used based on starting 
volume rather than RNA quantity, and 6 ul of total RNA was reverse-transcribed with 
universal poly-T primers in 20 ul reactions. In both cases, a 10 ul –reverse reaction contained 
2 ul of Reaction Buffer, 1 ul of Enzyme Mix, 0.5 ul of synthetic RNA spike-in (Uni Sp6), 
nuclease-free water and 3 ul of RNA. The RNA spike-in is a synthetic template that allows 
the control of the quality of the cDNA synthesis. The reaction was carried out at 42ºC for 60 
min and 95ºC for 5 min on a GeneAmp PCR System 9700 Thermal Cycler (Applied 
Biosystems). The cDNA samples were stored at -20ºC until further usage. 
The rest of steps were common for FFPE tissues, cell lines and plasma. cDNA was 10x 
diluted and amplified by qPCR with miRNA-specific primers optimized with LNA. Briefly, in a 
10 ul –reaction, 4 ul of diluted cDNA were mixed with 5 ul SYBR Green master mix and 1 ul 
PCR primer mix. The amplification conditions consisted of an initial step at 95ºC for 10 
minutes, followed by 50 cycles of 10 seconds at 95ºC and 1 minute at 60ºC. MiRNA 
expression levels were detected using ABI Prism Sequence Detection System 7900HT 
(Applied Biosystems). All reactions were performed in triplicate and no-template controls 
were included in each run. In order to assess amplification specificity, dissociation curves 
and replicate assays were examined and those miRNAs whose dissociation curve showed 
unspecific amplification or inconsistent replicate Cq values were removed from further 
analysis. MiR-103a-3p was used to normalize miRNA expression as it appears in the 
literature as widely-used endogenous control for miRNA qRT-PCR and was stably expressed 
among our samples. Relative expression was calculated using the comparative cycle 
threshold (∆∆Ct) method implemented in qBasePLUS software (Biogazelle). 
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2.4.2. Detection of mRNA by qRT-PCR 
Five hundred nanograms of total RNA was reverse transcribed using the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems) and random primers following 
manufacturer’s instructions. Briefly, in a 20 ul –reaction, 10 ul of template RNA were mixed 
with 2 ul of RT Buffer (10x), 0.8 ul of dNTP mix (100 mM), 2 ul of random primers (10x), 1 ul 
of MultiScribe Reverse Transcriptase (50 U/ul), 1 ul of RNAse inhibitor (20 U/ul) and 
nuclease-free water. The reaction mixture was incubated at 25ºC for 10 min, 37ºC for 2h 
and 85ºC for 5 min. The cDNA was then 10x diluted and amplified by qPCR with the use of 
FAM/NFQ fluorescently labeled probes TaqMan (Roche Universal Probe library, Roche), 
specific primers (Sigma-Aldrich, St. Louis, MO, USA) and TaqMan Universal PCR Maser Mix 
(Applied Biosystems). The primers and probes used are listed in Table 4. In brief, the 12.5 ul 
–reaction contained 1.25 ul of forward and reverse primers (10 uM), 0.125 ul of TaqMan 
probe (10 uM), water and 6.25 ul of TaqMan Universal PCR Master Mix (2x). The 
amplifications conditions consisted of an initial step at 95ºC for 10 minutes, followed by 45 
cycles of 15 seconds at 95ºC and 1 minute at 60ºC. mRNA expression levels were detected 
using ABI Prism Sequence Detection System 7900HT (Applied Biosystems). All reactions 
were performed in triplicate and no-template controls were included in each run. In 
addition, each set of primers was tested for efficacy using serial dilutions of a control cDNA 
sample. Normalization of mRNA expression was carried out using ACTB and MRLP19 as 
reference genes. Relative expression was calculated using the comparative cycle threshold 
(∆∆Ct) method implemented in qBasePLUS software (Biogazelle). 
Table 4. Oligonucleotide primers and probes used for mRNA qRT-PCR. 
Gene name Primers Sequence (5’-3’) 
BRCA1 Forward primer ttaaagaaagaaaaatgctga 
 Reverse primer ggtggtttcttccattgacc 
 Universal Probe Library #82 
ACTB Forward primer ccaaccgcgagaagatga 
 Reverse primer ccagaggcgtacagggatag 
 Universal Probe Library #64 
MRLP19 Forward primer ggaatgttatcgaaggacaag 
 Reverse primer caggaagggcatctcgtaag 
 Universal Probe Library #42 
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2.5. Statistical analysis 
Statistical analysis was performed using GraphPad PRISM 5 software (GraphPad 
Software, La Jolla, CA) and SPSS software package, version 17.0 (IBM). In all the analysis, a 
two-tailed p-value<0.05 was considered statistically significant. 
2.5.1. Differential expression and ROC curve analysis 
Kolmogorov–Smirnov test was used to analyze the normal distribution of the miRNA 
expression levels, and unpaired t test or Mann–Whitney test were applied when 
appropriate to evaluate differences in miRNA expression between two groups. MiRNA 
discrimination potential was analyzed by computing receiver operating characteristic (ROC) 
curves and calculating areas under the curves (AUC) with corresponding 95% confidence 
intervals (CI), as well as the optimal specificity and sensitivity values. For associations 
between miRNA expression levels and clinicopathologic characteristics of the patients at the 
time of breast cancer diagnosis, non-parametric Mann–Whitney test (two groups’ 
comparison) and Kruskal Wallis test (multiple groups’ comparison) were applied. 
2.5.2. Survival analysis 
Estimation of survival time distribution was performed using Kaplan-Meier method and 
differences between survival curves were assessed for statistical significance with log-rank 
test if the proportional hazard assumption was valid, or Gehan–Breslow–Wilcoxon test 
otherwise. A univariate Cox proportional hazards regression analysis was conducted to 
determine the impact of miRNA expression status on RFS. To adjust for other prognostic 
factors potentially acting as confounding variables (tumors size, age at diagnosis, Ki-67 
expression levels and nodal status), we used multivariate Cox proportional hazards 
regression model. The prognostic value of the miRNAs analyzed was tested by comparing 
patients with expression levels ≥median versus those with expression levels <median.  
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3. CELL LINES AND FUNCTIONAL STUDIES 
3.1. Breast cancer cell lines 
A panel of 6 human cell lines was used as a model to study functional effects of miRNA 
expression and inhibition. Five of them (MDA-MB-231, Hs578T, SKBR3, BT474 and MCF7) 
corresponded to sporadic breast tumors and were representative of the main molecular 
subtypes of breast cancer (Table 5). These cell lines were obtained from the Cancer 
Epigenetics Group at the Bellvitge Institute for Biomedical Research (Barcelona, Spain). The 
sixth cell line (HEK-293T) was derived from an embryonic kidney and was obtained from the 
Cytogenetics Group at the Spanish National Cancer Research Centre (Madrid, Spain).  
Table 5. Breast cancer cell lines used in this thesis. 
Breast cancer cell line Molecular subtype IHC markers 
MDA-MB-231 Triple negative ER-, PR-, Her2- 
Hs578T Triple negative ER-, PR-, Her2- 
SKBR3 Her2 ER-, PR-, Her2+ 
BT474 Luminal B ER-, PR+, Her2+ 
MCF7 Luminal A ER+, PR+, Her2- 
 
3.2. Manteinance and subculturing of cells 
Cell lines were grown in RPMI-1640 (Sigma-Aldrich) or Dulbecco’s Modified Eagle’s 
Medium (DMEM, Sigma-Aldrich) containing 10% fetal bovine serum, 1% 
penicillin/streptomycin and 0.5% fungizone (Gibco, Life Technologies). In the case of BT474 
cells, the medium was completed with 0.01 mg/ml of insulin (Sigma-Aldrich). Cells were 
maintained in an atmosphere of 5% CO2 in air at 37ºC and were passaged at approximately 
80-90% confluence.  
3.3. Luciferase reporter assay 
To verify direct binding of miR-498 and miR-187-5p to BRCA1, we performed target in 
vitro assays using luciferase reporter system (Figure 7). Pre-miRNA oligonucleotides (pre-
miR-498, pre-miR-187-5p, pre-miR-146a-5p and non-targeting control) were purchased 
from Ambion (Life Technologies). In brief, 100 ng of Firefly Luciferase-BRCA1 3’UTR 
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construct, together with 7.5 ng of Renilla Luciferase vector and 6 pmol (50 nM) of individual 
pre-miRNA oligonucleotides or mock transfection control, were transfected using 
Lipofectamine 2000 reagent (Invitrogen, San Diego, CA) into 293T cells in a 96-well plate 
format following manufacturer’s instructions. Cells were grown for 48h, after which cells 
were harvested and luciferase activity was assayed with Dual-Glo Luciferase Assay System 
(Promega) according to manufacturer’s instructions. Experiments were performed in 
triplicate and normalization was achieved using Renilla luciferase activity.  
 
Figure 7. Outline of the luciferase reporter assay. Firefly luciferase gene, with 3’UTR region of 
interest cloned immediately downstream of the stop codon, codes for an oxidative enzyme that 
converts luciferin substrate into oxiluciferin in a reaction that emits light. Photon emission is 
detected by luminometer, and the signal intensity is directly proportional to the amount of the 
enzyme. In the presence of a miRNA that binds to the 3’UTR and induces either mRNA degradation 
or translational inhibition, production of luciferase enzyme is reduced/abolished resulting in lower 
signal emission. 
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3.4. MiRNA transfection 
In order to express or inhibit miR-498, synthetic pre-miR-498 or anti-miR-498 
oligonucleotides were transfected into MCF7 or HS678T cells, respectively, using 
Oligofectamine reagent (Invitrogen). Pre-miRNA oligonucleotides were purchased from 
Ambion (Life Technologies) and anti-miRNA oligonucleotides from Exiqon. One day before 
transfection, cells were seeded in 6-well plates with 2 ml of growth medium without 
antibiotics to a density of 60%. Stock transfection mixes were made according to 
manufacturer’s instructions. Briefly, 5 ul of Oligofectamine reagent was diluted in 15 ul of 
Opti-MEM I Medium with L-glutamine (Invitrogen, CA, USA) and incubated 5 minutes at RT. 
In another tube, pre-miRNA or anti-miRNA oligonucleotides were diluted with Opti-MEM to 
a final concentration of 25nM. Both mixes were incubated together for 20 minutes at RT to 
allow complex formation between miRNA and lipids. To transfect cells, the growth media 
was removed and replaced with 800 ul of Opti-MEM media, and 200 ul of the appropriate 
transfection mix. Control cells were treated with a non-targeting miRNA or with no miRNA 
precursor or inhibitor (mock). Cells were incubated at 37ºC for 6 h, after which media was 
replaced with the same volume of fresh full growth media. At 48 hours after transfection 
cells were harvested for mRNA and/or protein analysis. 
3.5. Cell proliferation assay 
Cell proliferation assay was assessed by using water-soluble tetrazolium salt (WST-1) 
assay. HS578T cells were seeded in 96-well plates one day before transfection at 30-40% 
confluence in antibiotic-free media. Cells were transfected using Oligofectamine (Invitrogen) 
with 25 nM of anti-miR-498, non-targeting miRNA or mock transfection control. Cells were 
incubated in 10µl of WST-1 (Roche) diluted in 200 μl normal culture medium at 37ºC for 2h. 
The assay is based on the cleavage of the red WST-1 tetrazolium salt to yellow soluble 
formazan by metabolically active cells. The formazan dye is quantified by optical density at 
450 nm by means of a multi-well spectrophotometer (Perkin Elmer, Massachusetts, USA). 
Cell viability was determined at 24, 48, 72, 96, 120 or 144 hours after transfection. Each 
value represents the average of six independent replicates. 
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4. PROTEIN-BASED ASSAYS 
4.1.  Protein extraction and quantification 
Since BRCA1 protein is predominantly expressed in the nucleus, nuclear protein 
extraction was performed. Cells were trypsinized and washed twice with PBS 1X. Cell lysates 
were prepared by resuspending cell pellets in 200 ul of RSB buffer (Tris 10 mM pH 7.5, NaCl 
10 mM and MgCl2 3 mM,) with protease inhibitor (Roche) per 106 of cells, and by incubating 
20 min on ice. After centrifugation at 2000 rpm for 5 min at 4ºC, supernatant contains the 
cytoplasmic fraction and the remaining pellet the nuclear fraction. In order to remove any 
contaminating cytoplasm, pellets were again resuspended in 200 ul of RSB buffer containing 
protease inhibitor and centrifuged, and the remaining pellet was washed twice with 200 ul 
of RSB buffer without protease inhibitor. The pellet was then dissolved in 20 ul of NB buffer 
(Tris 10 mM pH 7.5, NaCl 0.4 mM and EDTA 1 mM) containing protease inhibitor, shaked in a 
rotor for 15 min at 4ºC and centrifuged at 11000 rpm for 5 min at 4ºC. Supernatant was 
collected and protein concentration was measured by Lowry assay method (Bio-Rad 
laboratories, Hercules, CA, USA) using bovine serum albumin (BSA) (Sigma-Aldrich) to create 
a standard curve with known concentrations of protein. 
4.2.  Western blot analysis 
Equal amounts of protein (50µg) were separated by SDS-PAGE on 6% home-made gels 
at 75 V for 1.5 hour using a Mini-PROTEAN Tetra cell electrophoresis chamber (Bio-Rad). 
Briefly, 10 ml of resolving gel contained 2 ml of 30% acrylamide, 2.5 ml of 1.5 M Tris (Ph 
8.8), 0.1 ml of 10% SDS, 0.1 ml of 10% ammonium persulfate, 0.008 ml of TEMED and water; 
and 5 ml of 5% stacking gel contained 0.83 ml of 30% acrylamide, 0.63 ml of 1 M Tris (Ph 
6.8), 0.05 ml of 10% SDS, 0.05 ml of 10% ammonium persulfate, 0.005 ml of TEMED and 
water. After electrophoresis, proteins separated on the gel were electrotransferred during 
1h at 60V to nitrocellulose membrane (Whatman) using 1x NuPAGE Transfer buffer 
(Invitrogen) with 10% methanol and a Mini Trans-Blot Cell (Bio-Rad). The membranes were 
blocked overnight at 4ºC with 5% non-fat dry milk in 1xTBS with 0.05% Tween (TBS-T) 
detergent, washed with TBS-T and incubated with primary antibody overnight at 4ºC. For 
BRCA1 detection, mouse antibody against BRCA1 (OP92, Calbiochem, Darmstadt, Germany) 
80 
 
at 1/100 dilution was used. For HSP70/HSC70 detection (loading control), mouse antibody 
against HSP70/HSC70 (ADI-SPA-820, Enzo Life Sciences) at 1/2000 dilution was used. Next, 
membranes were washed three times for 10 minutes with TBS-T and incubated with the 
corresponding horseradish peroxidase (HRP) conjugated (Dako, Glostrup, Denmark) 
secondary antibody at 1/10000 dilution for 2 hours at room temperature. After washing the 
membranes three times for 10 minutes with TBS-T, the antibody visualization was carried 
out with Amersham ECL Western Blotting Detection Reagent (GE Healthcare Life Sciences 
Buckinghamshire, UK) and Ortho CP-G Plus x-ray films (AGFA, Mortsel, Belgium). Films were 
scanned and signal was quantified using Image J program. BRCA1 protein content was 
determined relative to HSP70/HSC70 protein content.  
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1. DEREGULATED MICRORNAs IN BREAST CANCER MOLECULAR 
SUBTYPES 
A large number of studies have explored the value of gene expression profiling in breast 
cancer, thus leading to the stratification of breast tumors into at least four major subtypes: 
luminal A, luminal B, Her2 and triple negative (Hu et al., 2006; Perou et al., 2000; Sorlie et 
al., 2001; Sorlie et al., 2003). However, few reports have investigated the usefulness of 
miRNA expression profiling in breast cancer diagnosis. Taking into account the important 
role that miRNAs play in tumorigenesis and their ability to classify human tumors accurately 
(Lu et al., 2005), the first objective of this thesis was to identify miRNAs associated with 
breast tumors and with the main molecular subtypes of breast cancer, and to explore their 
discriminatory potential. 
 
1.1. miRNA expression profiles in breast tumors and normal breast tissues 
We explored the expression of 1919 human miRNAs in 122 primary breast tumors (31 
triple negative, 27 Her2, 33 luminal B and 31 luminal A) and 11 normal breast tissues by 
using LNA based microarrays. After filtering the data to remove miRNAs with low expression 
variation across samples (VAR<0.03), we obtained 698 miRNAs for further analysis. 
Unsupervised hierarchical clustering (Figure 8) showed that miRNA expression profiling 
clearly separated breast tumors from normal breast tissues, although a perfect stratification 
was not observed according to the molecular subtype of the samples. While most triple 
negative and luminal B tumors clustered as two homogenous groups, luminal A and Her2 
tumors were dispersed across the cluster exhibiting heterogeneous miRNA expression 
profiles. The right branch of the cluster, in which normal breast tissues were included, 
consisted of a higher proportion of ER-positive and low-moderate grade tumors, while the 
left branch was enriched in ER-negative and high grade tumors. 
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Figure 8. Unsupervised hierarchical clustering (Pearson correlation, average linkage clustering) over 
698 miRNAs in 133 breast samples. Each column represents a breast sample and each row 
corresponds to a miRNA. Heatmap colors indicate relative miRNA expression: over-expression is 
represented in red and repression in green. Molecular subtype of the tumors, inmunohistochemical 
marker for ER and histologic grade are represented by color labels. 
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1.2. Identification of miRNAs specifically and commonly deregulated in 
breast cancer molecular subtypes 
In order to detect significantly deregulated miRNAs in breast tumors and breast cancer 
molecular subtypes, supervised analysis was performed. A total of 194 miRNAs showed 
significant differential expression (FDR<0.05) between breast tumors and normal breast 
tissues: 117 were upregulated in breast tumors while 77 were downregulated. Eleven of 
these differentially expressed miRNAs had a fold change (FC)≥2 (Table 6).  
Table 6. Top 11 miRNAs with the greatest difference in expression between breast tumors and 
normal breast tissues (FDR<0.05, FC≥2).  
Gene Name  FDR  Fold Change  Median Normal 
Breast 
Median Breast 
Tumors 
miR-125b-5p  1E-07 4.1 ↓ 10.9 8.6 
miR-21-5p  9.07E-05 3.2 ↑ 6.5 8.3 
miR-3613-3p  7.16E-05 3.1 ↑ 7.3 8.7 
miR-4668-5p  0.000194 2.8 ↑ 6.6 8.2 
miR-4516  1.77E-05 2.5 ↓ 11.0 9.7 
miR-548as-3p 0.000167 2.4 ↑ 6.4 7.7 
miR-3656  2.00E-07 2.2 ↓ 9.4 8.4 
miR-4488 1.80E-06 2.2 ↓ 8.8 7.7 
miR-5704  5.04E-05 2.2 ↑ 7.3 8.3 
miR-141-3p  0.003198 2.0 ↑ 7.3 8.0 
miR-638  0.000536 2.0 ↓ 8.7 7.9 
FDR: False Discovery Rate adjusted p-value. 
 
Comparison of the miRNA expression profile of each molecular subtype with the normal 
breast tissues led to the identification of 335, 98, 157 and 249 differentially expressed 
miRNAs in triple negative, Her2, luminal B and luminal A tumors, respectively (Figure 9A). In 
order to detect miRNAs specifically deregulated in each molecular subtype, we compared 
these results by using a Venn diagram. We identified 105, 1, 39 and 17 miRNAs specific for 
triple negative, Her2, luminal B and luminal A tumors, respectively, as well as 52 miRNAs 
commonly deregulated in the four molecular subtypes (Figure 9B and Supplementary Table 
S1).  
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Figure 9. Deregulated miRNAs in breast cancer molecular subtypes. A) miRNAs differentially 
expressed (FDR<0.05) between normal breast tissues and each molecular subtype. B) Venn diagram 
showing miRNAs specifically up or downregulated in each molecular subtype, and those commonly 
deregulated in all the subtypes. TN: triple negative, H2: Her2, LB: luminal B, LA: luminal A, N: normal 
breast tissues.  
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1.3. miRNA signatures for breast tumor and breast cancer molecular 
subtype prediction  
To identify the smallest set of miRNAs discriminating breast tumors from normal breast 
tissues, and each molecular subtype from the rest of subtypes, five miRNA microarray 
classifiers were generated. Breast tissues were divided into two groups: a training set (61 
breast tumors and 7 normal breast tissues) used for the discovery phase and a test set (61 
breast tumors and 4 normal breast tissues) used for the validation phase. Both series 
comprised a similar number of samples from each molecular subtype. Clinicopathologic 
characteristics of patients included in each series are shown in Table 7. 
The predictors were built with samples from the training set and the 698 miRNAs used 
in the differential expression analysis. For the identification of the most representative 
miRNAs we used correlation feature selection and employed 5-fold cross-validation 
repeated 10 times to estimate how accurately the predictive model will perform in an 
independent data set. We used different algorithms that have been shown to function well 
with microarray data: support vector machines (SVM), k-nearest neighbor (KNN) and 
Random Forest (RF), and we selected SVM because it showed the best performance for the 
five different situations, producing the minimal root median square error (RMSE) and 
maximal accuracy, Mathews correlation coefficient (MCC) and AUC (Supplementary Table 
S2). Using this algorithm, we generated a 25-miRNA signature for breast tumor prediction 
with 100% sensitivity and 83% specificity, and a 8, 7, 16 and 3-miRNA signature for triple 
negative, Her2, luminal B and luminal A prediction, respectively, with high sensitivity (>93%) 
and specificity (99%). The list of miRNAs that compose each signature is shown in Table 8. 
Some of the miRNAs identified were detected as specifically deregulated (in the case of 
molecular subtypes) or commonly deregulated (in the case of breast tumors) in the 
differential expression analysis.  
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Table 7. Patients’ clinicopathologic characteristics at the time of breast cancer diagnosis. 
Parameter  Training set (n=61)  Test set (n=61) 
Age, years  n=45 n=45 
Mean 62 59 
Range 33-89 28-82 
Tumor size  n=42 n=39 
T1 (≤ 2cm) 23 (55%) 21 (54%) 
T2 (2.1-5cm) 14 (33%) 15 (38%) 
T3/T4 (>5cm) 5 (12%) 3 (8%) 
Grade  n=39 n=38 
I 4 (10%) 1 (3%) 
II 10 (26%) 15 (39%) 
III 25 (64%) 22 (58%) 
Nodes  n=41 n=39 
negative 16 (39%) 16 (41%) 
positive 25 (61%) 23 (59%) 
Stage n=40 n=36 
I 12 (30%) 11 (30%) 
II 17 (43%) 15 (42%) 
III 8 (20%) 9 (25%) 
IV 3 (7%) 1 (3%) 
ER n=61 n=61 
negative  28 (46%) 30 (49%) 
positive 33 (54%) 31 (51%) 
PR n=61 n=61 
negative 30 (49%) 32 (52%) 
positive 31 (51%) 29 (48%) 
KI-67 n=60 n=59 
low (<14%)  15 (25%) 17 (29%) 
intermediate-high (≥14%) 45 (75%) 42 (71%) 
Her2 n=60 n=61 
negative 45 (75%) 45 (74%) 
positive 15 (25%) 16 (26%) 
Subtype  n=61 n=61 
Luminal A 16 (26%) 15 (25%) 
Luminal B 17 (28%) 16 (26%) 
Her2 13 (21%) 14 (23%) 
Triple negative 15 (25%) 16 (26%) 
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Table 8. Performance of the 5 miRNA signatures for the prediction of breast tumors and breast 
cancer molecular subtypes.  
Classifier Dataset Accur. 
(%) 
Sensitiv. 
(%) 
Specific. 
(%) 
miRs 
(n) 
miRNA signature 
Breast 
tumors 
Training 
61 BT 
7 NT 
98 100 83 25 miR-125b-5p*,miR-3613-3p*, 
miR-4668-5p*,miR-3656*,miR-
5704*,miR-3676-3p,miR-3196, 
miR-3941*,miR-585,miR-1264*, 
miR-200a-3p*,miR-1273g-3p, miR-
5581-3p,miR-877-5p*,miR-96-
5p*,miR-744-3p*,miR-2276*,miR-
342-5p*,miR-760*,miR203*, 
miRPlus-A1086,miR-185-5p*,miR-
20b-5p,miR-4521*,miR-4692 
Test 
61 BT 
4 NT 
100 100 100 
Triple 
negative 
tumors 
Training 
15 TN 
46 RT 
98 95 99 8 miR-125b-5p,miR-126-3p*,miR-
214-3p*,miR-29c-3p,miR-4290, 
miR-3149,miR-10b-5p*,miR-
5193* Test 
16 TN 
45 RT 
98 94 100 
Her2 
tumors 
Training 
13 H2 
48 RT 
98 93 99 7 miR-5704,miR-3676-3p,miR-
1264,miR-3195,miR-205-5p, miR-
4536-3p,miR-4692 
Test 
13 H2 
48 RT 
100 100 100 
Luminal B 
tumors 
Training 
17 LB 
44 RT 
97 93 99 16 miR-205-5p,miR-320a,miR-10a-
5p,miR-130a-3p,miR-1273g-3p, 
miR-15b-5p*,miR-4667-5p,miR-
4633-5p,miR-4800-5p,miR-708-
5p,miR-1321,miR-125b-1-3p, miR-
374a-5p,miR-3912,miR-221-3p, 
miR-3161 
Test 
16 LB 
45 RT 
95 94 95 
Luminal A 
tumors 
Training 
16 LA 
45 RT 
98 97 99 3 miR-3676-3p,miR-532-3p,miR-22-
5p 
Test 
15 LA 
46 RT 
96 93 97 
*miRNAs detected as specifically deregulated (in the case of molecular subtypes) or commonly 
deregulated (in the case of breast tumors) in the previous analysis. BT: breast tumors, NT: normal 
breast tissues, TN: triple negative, H2: Her2, LB: Luminal B, LA: Luminal A, RT: Rest of tumors.  
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In order to validate the discriminatory potential of the 5 miRNA signatures, we classified 
an independent series of 65 samples (test set) in a blind approach. Patients in the test set 
were correctly identified with 100% sensitivity and 100% specificity using the breast tumor 
miRNA signature, 94% sensitivity and 100% specificity using the triple negative miRNA 
signature, 100% sensitivity and 100% specificity using the Her2 miRNA signature, 94% 
sensitivity and 95% specificity using the luminal B miRNA signature, and 93% sensitivity and 
97% specificity using the luminal A miRNA signature (Table 8).  
 
1.4. Pathway enrichment analysis 
Given the fact that a single miRNA can target a large number of mRNA transcripts, 
aberrant expression of a set of miRNAs could have significant effect on cellular function by 
affecting multiple signaling pathways. To get more insight into the biological relevance of 
deregulated miRNA expression in breast cancer molecular subtypes, we used Diana miRPath 
web-based computational tool and investigated biological processes that are predicted to 
be targeted collectively by each of the 5 miRNA signatures identified. KEGG pathway 
enrichment analysis has revealed that the miRNAs that compose each signature are 
expected to regulate multiple pathways that are known to be relevant for cancer 
development and progression, such as PI3K-Akt, MAPK, Wnt, mTOR, p53, Notch, ErbB, 
VEGF, TGF-beta and HIF-1 signaling pathways. Top 10 statistically significant biological 
functions enriched in each miRNA signature are shown in Table 9. Interestingly, ErbB 
signaling pathway is one of the most significantly overrepresented pathways in the Her2 
miRNA signature, indicating that the deregulation of miR-1264, miR-205-5p, miR-4536-3p 
and miR-4692 may contribute to the alteration of the ErbB signaling pathway in this group 
of tumors. Of note, some of the biological functions enriched in each miRNA signature are 
common to other cancers such as chronic myeloid leukemia, thyroid, prostate, endometrial, 
bladder or small cell lung cancer, suggesting potential similarities in the molecular 
mechanisms that operate in particular breast cancer molecular subtypes and different types 
of cancer. 
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Table 9. Top 10 significantly enriched signaling pathways associated with the different miRNA 
sigantures.  
 
MiRNA signature KEGG pathway p-value #genes #miRNAs 
Breast tumors  
25-miR signature  
MAPK signaling pathway 2.56E-38 131 21 
Regulation of actin cytoskeleton 8.01E-31 108 19 
Ubiquitin mediated proteolysis 2.40E-29 82 16 
Axon guidance 1.58E-27 72 18 
Wnt signaling pathway 2.22E-25 80 21 
Neurotrophin signaling pathway 5.47E-25 69 18 
Gap junction 1.25E-21 55 18 
Endocytosis 7.46E-21 99 17 
ErbB signaling pathway 7.84E-21 53 17 
PI3K-Akt signaling pathway 9.03E-21 151 18 
Triple negative 
tumors 8-miR 
signature 
PI3K-Akt signaling pathway 9.54E-17 93 8 
Protein digestion and absorption 1.18E-14 33 6 
ECM-receptor interaction 1.18E-14 29 8 
Focal adhesion 2.88E-14 60 8 
Small cell lung cancer 1.14E-11 30 7 
MAPK signaling pathway 2.58E-08 66 7 
Insulin signaling pathway 2.58E-08 39 8 
Lysine degradation 7.43E-08 17 6 
mTOR signaling pathway 9.06E-08 22 8 
Prostate cancer 1.05E-07 27 6 
HER2 tumors  
7-miR signature  
Adherens junction 5.06E-12 22 3 
Thyroid cancer 1.80E-11 12 3 
Prostate cancer 1.01E-10 22 3 
Endometrial cancer 1.97E-09 15 3 
Bladder cancer 1.56E-06 12 3 
Wnt signaling pathway 1.71E-06 28 5 
Glioma 2.44E-06 16 4 
ErbB signaling pathway 6.28E-06 16 4 
Endocrine and other factor-regulated 
calcium reabsorption 1.92E-05 14 3 
Aldosterone-regulated sodium 
reabsorption 3.99E-05 10 3 
Luminal B tumors 
16-miR signature  
TGF-beta signaling pathway 4.08E-38 43 12 
Prostate cancer 8.62E-25 42 12 
mTOR signaling pathway 5.26E-24 33 12 
Pathways in cancer 5.43E-19 115 15 
Chronic myeloid leukemia 7.96E-18 34 11 
Endocytosis 5.76E-16 75 13 
Wnt signaling pathway 4.51E-14 60 13 
PI3K-Akt signaling pathway 4.99E-14 108 13 
Focal adhesion 7.26E-13 70 14 
ABC transporters 1.26E-12 21 9 
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Luminal A tumors 
3-miR signature   
Mucin type O-Glycan biosynthesis 0.009179 4 2 
Valine, leucine and isoleucine 
biosynthesis 0.019153 1 1 
Fanconi anemia pathway 0.019153 6 2 
MAPK signaling pathway 0.019153 19 2 
Endocytosis 0.019153 16 2 
Focal adhesion 0.019153 16 2 
Fc gamma R-mediated phagocytosis 0.019153 9 2 
Pentose phosphate pathway 0.032454 3 2 
PI3K-Akt signaling pathway 0.032454 22 2 
Fc epsilon RI signaling pathway 0.032454 7 2 
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2. CIRCULATING MICRORNAs IN EARLY BREAST CANCER 
DETECTION 
Circulating miRNAs are attracting the attention of researchers as they are highly stable, 
resistant to degradation and can be easily obtained by non-invasive procedures (Chen et al., 
2008). Although it is unclear how these extracellular miRNAs are liberated into plasma, 
there is evidence that some miRNAs are selectively released from malignant mammary 
epithelial cells while retained by non-malignant cells (Pigati et al., 2010). Taking into account 
the potential clinical relevance of circulating miRNAs in breast cancer, the second objective 
of this thesis was to study in plasma the status of the most deregulated miRNAs identified in 
breast tumors and to analyze their utility as non-invasive biomarkers for early breast cancer 
detection. 
 
2.1. Validation of the most relevant miRNAs in breast tumors by qRT-PCR  
We selected miRNAs with the smallest FDR and highest FC when comparing breast 
tumors and normal breast tissues and tried to validate them by qRT-PCR in 44 tumors from 
the test set (11 from each molecular subtype) and 12 normal breast tissues. A total of 19 
miRNAs were selected: 10 from the breast tumor classifier and 9 from the differential 
expression analysis. Unfortunately, 8 were discarded due to unspecific amplification or no 
amplification (miR-3613-3p, miR-4668-5p, miR-5704, miR-1264, miR-5581-3p, miR-548as-
3p, miR-3686, miR-4419b), and therefore 11 could be analyzed: 5 from the breast tumor 
classifier and 6 from the differential expression analysis. MiR-103a-3p was used for data 
normalization as it is a widely-used endogenous control for miRNA qRT-PCR and was stably 
expressed among our samples. Statistical analysis led to the validation of all of them (p-
value<0.05) except miR-1273g-3p. Hence miR-183-3p, miR-96-5p, miR-142-3p, miR-141-3p, 
miR-21-5p and miR-200a-3p were confirmed to be significantly upregulated in breast 
tumors whereas miR-125b-5p, miR-3656, miR-638 and miR-505-5p were confirmed to be 
downregulated (Figure 10). 
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Figure 10. Validation of most relevant miRNAs by qRT-PCR in breast tumors and normal breast 
tissues. Scatter plots show relative expression levels of miR-183-3p, miR-96-5p, miR-142-3p, miR-
141-3p, miR-21-5p, miR-200a-3p, miR-125b-5p, miR-3656, miR-638 and miR-505-5p in 44 breast 
tumors (T) and 12 normal breast tissues (N).   
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2.2. From tumor to plasma: analysis of circulating miRNAs 
 In order to evaluate the expression of our selected miRNAs in plasma, amplification 
by qRT-PCR was performed in 26 healthy individuals, 36 pretreated and 47 postreated 
breast cancer patients. Clinicopathologic details of patients included in each series are 
shown in Table 10. Of note, most of the patients had an early-stage breast cancer. Among 
10 miRNAs analyzed, 9 had detectable levels of expression in plasma and only miR-183-3p 
could not be detected. Comparison of the expression levels in pretreated breast cancer 
patients and normal individuals led to the identification of 5 differentially expressed miRNAs 
in plasma: miR-3656, miR-505-5p, miR-125b-5p, miR-21-5p and miR-142-3p. In addition, 
although not significant, miR-96-5p showed a trend (p-value<0.1). Interestingly, some of the 
miRNAs analyzed were deregulated in opposite directions when compared with tumors. 
That is, miR-21-5p, miR-142-3p and miR-96-5p were both overexpressed in breast tumors 
and plasma from breast cancer patients, whereas miR-3656, miR-505-5p and miR-125b-5p 
were downregulated in breast tumors but upregulated in plasma from breast cancer 
patients (Figure 11). A selective release of certain miRNAs from tumors to plasma might be 
the explanation for this discordance.  
Next we compared the expression levels of the 5 significant miRNAs and the one with p-
value<0.1 in pretreated breast cancer patients and patients who underwent surgery and/or 
systemic therapy. While miR-125b-5p, miR-142-3p and miR-96-5p did not show a significant 
change in their levels, the expression of miR-3656, miR-21-5p and miR-505-5p was 
significantly reduced in plasma after treatment, suggesting that these miRNAs may be 
sensitive to changes in tumor mass (Figure 11).   
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Table 10. Patients’ clinicopathologic characteristics at the time of breast cancer diagnosis. 
Parameter 
Plasma Pretretaed - 
Discovery (n=36) 
Plasma Postreated - 
Discovery (n=47) 
Plasma Pretreated - 
Validation (n=114) 
Age, years  n=35 n=46 n=114 
Mean 57 50 57 
Range 33-82 28-74 28-85 
Tumor size  n=35 n=33 n=99 
T1 (≤2cm) 26 (74%) 20 (61%) 69 (70%) 
T2 (2.1-5cm) 8 (23%) 13 (39%) 30 (30%) 
T3/T4 (>5cm) 1 (3%) 0 0 
Grade  n=33 n=34 n=102 
I 7 (22%) 4 (12%) 16 (16%) 
II 13 (39%) 10 (29%) 48 (47%) 
III 13 (39%) 20 (59%) 38 (37%) 
Nodes  n=34 n=42 n=107 
negative 20 (59%) 19 (45%) 63 (59%) 
positive 14 (41%) 23 (55%) 44 (41%) 
Stage n=34 n=32 n=96 
I 18 (53%) 10 (32%) 36 (38%) 
II 12 (35%) 19 (59%) 48 (50%) 
III 3 (9%) 3 (9%) 12 (12%) 
IV 1 (3%) 0 0 
ER n=36 n=42 n=113 
negative  10 (28%) 16 (38%) 28 (25%) 
positive 26 (72%) 26 (62%) 85 (75%) 
PR n=34 n=42 n=113 
negative 9 (26%) 19 (45%) 35 (31%) 
positive 25 (74%) 23 (55%) 78 (69%) 
KI-67 n=34 n=35 n=113 
low (≤14%)  10 (29%) 9 (26%) 31 (27%) 
intermediate-high (>14%) 24 (71%) 26 (74%) 82 (73%) 
Her2 n=34 n=39 n=112 
negative 26 (76%) 30 (77%) 78 (70%) 
positive 8 (24%) 9 (23%) 34 (30%) 
Subtype  n=36 n=36 n=113 
Luminal A 10 (28%) 9 (25%) 33 (29%) 
Luminal B  16 (44%) 14 (39%) 52 (46%) 
Her2  4 (11%) 5 (14%) 9 (8%) 
Triple negative 6 (17%) 8 (22%) 19 (17%) 
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Figure 11. Relative expression levels of circulating miRNAs deregulated in the plasma of 36 
pretreated breast cancer patients (Pre) in comparison with 26 healthy individuals (N). Although not 
significant, miR-96-5p showed a trend (p-value<0.1). In addition, miRNA plasma concentration was 
quantified in 47 postreated breast cancer patients (Post).  
 
2.3. Marker validation 
The 5 significant miRNAs identified were then subjected to validation in a second set of 
plasma from 114 pretreated breast cancer patients and 116 healthy women. Since miR-96-
5p showed some evidence in the previous analysis, we decided to include this miRNA in the 
validation stage as well. Table 10 summarizes the clinicopathologic features of the patients, 
showing again a high proportion of early-stage breast cancers. The expression levels of miR-
505-5p, miR-125b-5p, miR-21-5p and miR-96-5p were confirmed to be significantly 
overexpressed in the plasma of breast cancer patients (Figure 12A). ROC curve analysis was 
performed to evaluate the diagnostic utility of these miRNAs. The resultant curves showed 
that miR-505-5p and miR-96-5p were the most valuable biomarkers for discriminating 
patients from healthy individuals, with AUC of 0.7213 (95% CI: 0.6558 to 0.7867, p<0.0001) 
and 0.7167 (95% CI: 0.6507 to 0.7827, p<0.0001), respectively, and sensitivity and specificity 
at the optimal cutoff of 75% and 60% for miR-505 and 73% and 66% for miR-96-5p, 
respectively. MiR-125b-5p and miR-21-5p showed AUC of 0.6368 (95% CI: 0.5642 to 0.7093, 
p<0.03699) and 0.6070 (95% CI: 0.5336 to 0.6803, p<0.03742), respectively (Figure 12B). 
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Figure 12. Circulating miRNAs validated as being overexpressed in the plasma of 114 breast cancer 
patients (Pre) when compared with 116 healthy women (N). A) Relative expression levels of miR-
505-5p, miR-96-5p, miR-125b-5p and miR-21-5p with their corresponding p-values. B) ROC curves for 
each miRNA and the resultant area under the curve (AUC). 
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2.4. Association between circulating miRNA expression and 
clinicopathologic characteristics 
We further compared the expression of circulating miR-505-5p, miR-125b-5p, miR-21-
5p and miR-96-5p with clinicopathologic characteristics in the 114 pretreated breast cancer 
patients. The variables evaluated were: age of the patient at diagnosis, tumor size, histologic 
grade, lymph node, ER, PR and Her2 status, ki-67 levels and molecular subtype. Non-
parametric Mann–Whitney test (for two groups’ comparison) and Kruskal Wallis test (for 
multiple groups’ comparison) were applied. Significant higher levels of miR-505-5p were 
observed in older patients, lower grade and ER positive tumors. Significant differences were 
also observed among molecular subtypes, with luminal A tumors with the highest levels of 
miR-505-5p (Figure 13). No significant associations between circulating miR-125b-5p, miR-
21-5p and miR-96-5p and clinicopathologic features were detected.  
 
Figure 13. Association between circulating miR-505-5p expression and different clinicopathologic 
characteristics in 114 pretreated breast cancer patients. A) age at diagnosis, B) histologic grade, C) 
ER status, and D) molecular subtype. 
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3. PROGNOSTIC MICRORNAs IN TRIPLE NEGATIVE BREAST 
CANCER PATIENTS 
Triple negative breast cancer (TNBC) is a very aggressive form of breast cancer with 
higher recurrence rates and greater likelihood of death compared to other breast cancer 
subtypes (Dent et al., 2007). Moreover, the lack of response to endocrine and anti-Her2 
therapies makes its treatment an extremely challenging process. Taking into account the 
absence of prognostic and predictive markers in this subtype of breast cancer, the third 
objective of this thesis was to identify miRNAs that can distinguish at the time of diagnosis 
between high and low risk TNBC patients. This subclassification would permit the 
administration of different treatments to patients with different clinical outcomes. 
 
3.1. miRNAs diferentially expressed in node-positive triple negative 
patients with different outcome  
Since nodal status is known to be an independent prognosis factor for breast cancer, we 
decided to explore if this factor was also associated with survival in our series of 21 triple 
negative tumors with available follow-up information. As expected, nodal status divided the 
patients in two groups: those with good prognosis (node-negative, 0.8 cumulative 
proportion of surviving) and those with worse prognosis (node-positive, 0.4 cumulative 
proportion of surviving) (Figure 14A). Since node-positive triple negative tumors were 
associated with a more variable outcome, we decided to focus on this group of patients to 
identify miRNAs linked to prognosis. 
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Figure 14. Kaplan-Meier survival curves of two different cohorts of triple negative patients based on 
nodal status: A) 20 patients used for microarray and qRT-PCR expression analysis, and B) 22 patients 
used for qRT-PCR expression analysis. Patients at risk at the indicated time intervals are shown at the 
bottom of the graph.  
 
 
Follow-up studies have demonstrated that the prognosis of TNBC patients is highly time 
dependent, with some patients experiencing disease recurrence in the first 3-5 years 
following diagnosis and other patients having excellent long term survival (Liedtke et al., 
2008; Mulligan et al., 2008). In order to detect differentially expressed miRNAs between 
node-positive triple negative patients with RFS shorter than 5 years and patients with longer 
RFS, differential expression analysis was performed with the 698 miRNAs obtained after 
microarray data filtering. A total of 17 miRNAs showed significant differential expression 
(FDR<0.05) and all of them were downregulated in triple negative patients with worse 
prognosis (Figure 15).  
 
Figure 15. miRNAs differentially expressed (FDR<0.05) between 6 node-positive triple negative 
patients with RFS shorter than 5 years and 4 node-positive triple negative patients with longer RFS. 
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3.2. miRNAs associated with recurrence in node-positive triple negative 
patients 
We performed survival analysis of node-positive triple negative patients to investigate 
associations between the expression levels of the 17 differentially expressed miRNAs and 
RFS. By using univariate Cox proportional hazards regression analysis we identified 4 
miRNAs significantly related to outcome: let-7b-5p, miR-195-5p, miR-24-3p and miR-30c-5p 
(hazard ratio (HR): 8.957; 95% confidence interval (CI): 1.024-78.310, p=0.048) (Figure 16).  
 
Figure 16. Kaplan-Meier survival curves of 10 node-positive triple negative patients based on the 
expression of let-7b-5p, miR-195-5p, miR-24-3p and miR-30c-5p. Patients at risk at the indicated 
time intervals are shown at the bottom of each graph. 
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3.3. Validation of prognostic miRNAs in triple negative patients 
To validate the prognostic value of let-7b-5p, miR-195-5p, miR-24-3p and miR-30c-5p, 
we analyzed their expression levels by qRT-PCR in the same 21 triple negative patients plus 
a second cohort of 22 triple negative patients. In this second cohort we could also observe a 
strong relationship between nodal status and clinical outcome, with all node-negative 
patients surviving after 5 years of diagnosis and node-positive patients having 40% 
probability of relapse-free survival (Figure 14B).  
Univariate Cox proportional hazards regression analysis confirmed that miR-30c-5p was 
significantly associated with RFS in both node-positive (HR: 4.101; 95% CI: 1.264-13.299, 
p=0.019) and all triple negative patients (HR: 4.157; 95% CI: 1.350-12.800, p=0.013) (Figure 
17A,B). Likewise, miR-195-5p was significantly related to outcome in all triple negative 
patients (HR: 3.338; 95% CI: 1.171-9.516, p=0.024) and almost significant in node-positive 
triple negative patients (HR: 2.717; 95% CI: 0.898-8.217, p=0.077) (Figure 17C,D). In 
addition, the combination of miR-30c-5p and miR-195-5p showed a significant association 
with RFS, with patients having both miRNAs overexpressed experiencing a significantly 
better outcome than patients having both of them underexpressed (Figure 17E,F). 
Analysis of histopathological variables (tumors size, age at diagnosis, Ki-67 expression 
levels and nodal status) confirmed the association of tumor size (HR: 1.379; 95% CI: 1.154-
1.648, p<0.001) and nodal status (HR: 4.700; 95% CI: 1.347-16.399, p=0.015) with RFS. 
Multivariate Cox proportional hazards regression analysis including tumor size and nodal 
status revealed an independent association of miR-195-5p with RFS in both node-positive 
and all triple negative patients (Table 11). However, after adjustment for these cofactors, 
miR-30c-5p lost its association in node-positive patients and showed weak evidence in all 
triple negative patients, indicating that expression of this miRNA may be correlated with 
tumor size. In fact, we found that triple negative tumors expressing low levels of miR-30c-5p 
were significantly bigger than tumors expressing high levels (Supplementary Figure S1).     
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Figure 17. Kaplan-Meier survival curves of 24 node-positive triple negative patients (A, C, E) and the 
whole cohort of 43 triple negative patients (B, D, F) based on the expression of miR-30c-5p, miR-195-
5p and the combination of both. Patients at risk at the indicated time intervals are shown at the 
bottom of each graph.  
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Table 11. Multivariate Cox regression analysis of prognostic factors for RFS. 
 
 Patients Comparison p-value HR (95% CI) p(adj) 
MiR-30c-5p   
 Node-positive TN MiRNA overexpression vs 
underexpression 
0.010 2.649 (0.720-9.749) 0.143 
 Tumor size  1.251 (1.013-1.545) 0.037 
 All TN  MiRNA overexpression vs 
underexpression 
0.006 3.322 (0.964-11.447) 0.057 
 Tumor size  1.210 (0.990-1.479) 0.063 
 Nodal status  6.466 (1.438-29.076) 0.015 
MiR-195-5p  
 Node-positive TN MiRNA overexpression vs 
underexpression 
0.059 7.924 (2.149-29.223) 0.002 
  Tumor size  1.523 (1.201-1.931) 0.001 
 All TN  MiRNA overexpression vs 
underexpression 
0.015 6.788 (2.101-21.931) 0.001 
  Tumor size  1.436 (1.165-1.770) 0.001 
  Nodal status  10.459 (2.178-50.228) 0.003 
P-values in the univariate analysis calculated with log-rank test; p(adj) as calculated in the 
multivariate analysis by using Cox regression model in node-positive triple negative patients and the 
whole series of triple negative patients with RFS as endpoint; TN, triple negative; HR, hazard ratio; 
CI, confidence interval. 
 
 
 
3.4. Pathway enrichment analysis 
To get more insight into the role of miR-30c-5p and miR-195-5p in TNBC, we used Diana 
miRPath web-based computational tool and investigated biological processes that are 
predicted to be targeted collectively by both miRNAs. KEGG pathway enrichment analysis 
has revealed that miR-30c-5p and miR-195-5p target different effectors of pathways 
involved in cell cycle, proliferation, angiogenesis, apoptosis and cell survival (Table 12). 
Hence, downregulation of miR-30c-5p and miR-195-5p in triple negative breast tumors 
could confer them enhanced proliferative, angiogenic and invasive potentials. 
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Table 12. Top 10 significantly enriched signaling pathways associated with miR-30c-5p and miR-195-
5p. 
KEGG pathway p-value Genes 
Ubiquitin mediated 
proteolysis 
4,78E-14 UBE2R2,BTRC,RFWD2,FBXW7,TRIM37,WWP1,CUL2, 
SMURF2,NEDD4L,UBE4A,HERC3,UBE2J1,UBE2I,SOCS3, 
CBLB,SKP2,SOCS1,UBE3C,BIRC6,SMURF1,UBE2Q1, 
RCHY1,UBE2K,SIAH1,NEDD4,UBE2F,UBE2D1,CDC27, 
UBE2D2,UBE2G1,CUL3,PPIL2,UBE4B 
B cell receptor signaling 
pathway 
3,24E-09 SOS2,RAF1,BCL10,KRAS,IKBKB,PPP3CA,NFAT5,PIK3CD, 
PPP3CB,NFATC2,PIK3R1,SOS1,DAPP1,AKT3,MAP2K1, 
RASGRP3,VAV3,NFATC3,LYN 
Prostate cancer 1,05E-08 SOS2,RAF1,BCL2,IGF1R,KRAS,IKBKB,AR,PIK3CD,CCND1, 
CCNE2,E2F3,PIK3R1,SOS1,AKT3,PDGFC,CCNE1,MAP2K1, 
FGFR1,FOXO1,PDGFA 
PI3K-Akt signaling 
pathway 
1,08E-08 PRLR,YWHAH,MYB,SOS2,ITGA9,ITGA8,COL24A1,CCND2, 
RAF1,BCL2,EFNA3,PPP2R2B,IGF1R,FGF20,PPP2R5C, 
KRAS,CDK6,IFNAR2,GHR,IKBKB,GNG10,DDIT4,PIK3CD, 
CCND1,EIF4E,CCNE2,PPP2R1A,EIF4B,PIK3R1,SOS1, 
IL2RA,YWHAZ,IRS1,INSR,FGF2,FGF18,AKT3,PDGFC, 
CCNE1,FOXO3,MAP2K1,ITGA4,ITGA6,VEGFA,FGFR1, 
PPP2R1B,FGF7,KDR,CSF1,BCL2L11,CCND3,PDGFA 
Neurotrophin signaling 
pathway 
1,08E-08 CAMK2D,SOS2,SH2B3,CAMK4,NTRK3,FRS2,RAF1,BCL2, 
KRAS,IKBKB,PIK3CD,MAPK8,KIDINS220,ARHGDIA, 
PIK3R1,SOS1,IRS1,RPS6KA3,AKT3,FOXO3,MAP2K1, 
IRAK2,PRDM4,RAP1B,ABL1,MAP3K5 
Long-term depression 1,14E-07 GNA12,GUCY1A3,CRHR1,GNA13,RAF1,IGF1R,GNAI3, 
KRAS,GRIA2,NOS1,PPP2R1A,GNAQ,MAP2K1,PRKG1, 
PPP2R1B,LYN 
Melanoma 1,92E-07 RAF1,IGF1R,FGF20,KRAS,CDK6,PIK3CD,CCND1,E2F3, 
PIK3R1,FGF2,FGF18,AKT3,PDGFC,MAP2K1,FGFR1,FGF7, 
PDGFA 
Non-small cell lung 
cancer 
2,61E-07 SOS2,RAF1,RARB,KRAS,CDK6,PIK3CD,CCND1,E2F3, 
PIK3R1,SOS1,AKT3,FOXO3,MAP2K1 
p53 signaling pathway 7,30E-07 ZMAT3,RFWD2,CCND2,CDK6,CHEK1,CASP3,CCND1, 
CCNE2,SHISA5,RCHY1,SESN1,SIAH1,TNFRSF10B,CCNE1, 
PPM1D,CCND3 
Cell cycle 1,25E-06 ESPL1,YWHAH,SMAD2,CDC14A,ORC2,CCND2,ORC4, 
DBF4,STAG2,WEE1,CDK6,CHEK1,CCNA1,CCND1,CCNE2, 
SKP2,E2F3,CDC14B,YWHAZ,TFDP1,CCNE1,CDC27,ABL1, 
CCND3,CDC25A 
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4. MICRORNA REGULATION OF BRCA1 GENE EXPRESSION IN 
SPORADIC TRIPLE NEGATIVE BREAST CANCER 
Sporadic triple negative tumors share many characteristics with BRCA1-mutated breast 
tumors, which reveals a possible role of BRCA1 dysfunction in the pathogenesis of sporadic 
TNBC. Despite being BRCA1+/+, most sporadic triple negative tumors have a reduced 
expression of the BRCA1 gene (Mueller and Roskelley, 2003; Turner et al., 2007), suggesting 
that other mechanisms might be involved in BRCA1 somatic inactivation. Considering the 
central role that miRNAs play in gene expression regulation, the last objective of this thesis 
was to investigate the involvement of miRNAs in BRCA1 regulation in sporadic triple 
negative breast cancer.  
 
4.1. Triple negative-specifc miRNAs predicted to target BRCA1  
In an attempt to identify miRNAs regulating the BRCA1 gene, five different target 
prediction algorithms (Miranda, Pita, TargetScan, Microtar and RNAhybrid) were used with 
the 78 miRNAs specifically upregulated in sporadic triple negative tumors identified in the 
first part of this thesis (Supplementary Table S1). We selected miR-498 and miR-187-5p 
since they were predicted to bind to the 3'UTR of the BRCA1 gene with high scores by at 
least two prediction methods (Table 13, Figure 18A). Overexpression of these two miRNAs 
in sporadic triple negative tumors could lead to reduced levels of BRCA1 expression.  
 
Table 13. miRNAs specifically overexpressed in triple negative breast tumors that are predicted to 
target the 3’UTR of BRCA1 by at least two prediction methods. 
miRNA 
mature 
Gene Agreement Miranda Pita Microtar RNAHybrid Targetscan 
Mean 
value 
hsa-miR-
498 
BRCA1 2 0.9006 - - - 1 0.9503 
hsa-miR-
187-5p 
BRCA1 3 0.9123 - 0.0022 0.0900 - 0.3348 
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4.2. BRCA1 is a target of miR-498 and miR-187-5p  
We investigated whether the 3’UTR of BRCA1 is a functional target of miR-498 and miR-
187-5p by using a reporter vector into which the entire 3’UTR of BRCA1 was inserted 
downstream of the firefly luciferase reporter gene. This reporter vector was transiently 
transfected into 293T cells together with pre-miR-498, pre-miR-187-5p, non-targeting 
control, positive control (pre-miR-146a-5p) or no miRNA precursor. Each experiment was 
performed in quadruplicate. An average of 35% and 50% reduction of reporter activity as 
compared to the mock transfection control was observed for miR-498 and miR-187-5p, 
respectively (Figure 18B), indicating that these miRNAs target BRCA1 3’UTR. Similar to 
previous studies, the degree of luciferase inhibition with miR-146a-5p reached 60%. 
 
 
Figure 18. Negative regulation of BRCA1 expression by miR-498 and miR-187-5p. A) Schematic 
representation of miRNA binding sites within the BRCA1 3’UTR. B) Relative luciferase activity of a 
reporter vector carrying the BRCA1 3’UTR downstream of the firefly luciferase gene. The vector was 
co-transfected with each of the indicated miRNA precursors or with no miRNA precursor (mock) into 
293T cells. Error bars represent standard deviation for four replicates of one representative 
experiment. Data were normalized versus the luciferase levels generated by the mock transfection. * 
p<0.05.  
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4.3. MiR-498 and miR-187-5p expression in breast tumors and breast 
cancer cell lines of different subtypes 
In the first part of this thesis, we found that miR-498 and miR-187-5p expression was 
increased in sporadic triple negative breast tumors but not in other subtypes when 
compared with normal breast tissues (Figure 19A). We next analyzed the expression of miR-
498 and miR-187-5p in 5 different breast cancer cell lines, including two triple negative 
(MDA-MB-231 and HS578T), one Her2 (SKBR3), one luminal B (BT474) and one luminal A 
(MCF7) cell line. We found that miR-498 was expressed at high levels in a triple negative cell 
line (HS578T) while miR-187-5p was highly expressed in a luminal cell line (BT474). 
Regarding BRCA1 expression, lower levels were found in the triple negative and the Her2 
cell lines when compared with the luminal cell lines (Figure 19B). Since we were interested 
in miRNAs with increased expression levels in triple negative cell lines and negatively 
correlated with BRCA1 expression levels, we decided to focus on miR-498 for following 
experiments. 
 
 
Figure 19. miR-498 and miR-187-5p expression levels in breast tumors and breast cancer cell lines of 
different subtypes. A) Relative expression of miR-498 and miR-187-5p in 11 normal breast tissues 
(N), 91 non triple negative tumors (non TN) and 31 triple negative tumors (TN). B) Relative 
expression of miR-498, miR-187-5p and BRCA1 in two triple negative (MDA-MB-231 and HS578T), 
one Her2 (SKBR3), one luminal B (BT474) and one luminal A (MCF7) breast cancer cell lines. Error 
bars represent standard deviation for triplicates of one representative experiment. 
110 
 
4.4. MiR-498-mediated regulation of BRCA1 in breast cancer cell lines 
Since miR-498 was expressed at high levels in HS578T cells and at low levels in MCF7 
cells, we next investigated the consequences of miR-498 inhibition in HS578T cell line and of 
miR-498 overexpression in MCF7 cell line. As expected, miR-498 inhibition led to an increase 
in the amount of BRCA1 (480% increase at the mRNA level and 164% increase at the protein 
level) while its overexpression produced a reduction of BRCA1 (38% decrease at the mRNA 
level), as compared with mock transfection (Figure 20). These results demonstrate that miR-
498 regulates the expression of BRCA1 in breast cancer cells. 
 
 
Figure 20. BRCA1 expression levels after miR-498 inhibition or overexpression. A) Relative mRNA 
levels of BRCA1 after transfection of HS578T cells with anti-miR-498, non-targeting control or no 
miRNA inhibitor. B) Western blot analysis of BRCA1 expression in HS578T cells after transfection 
with anti-miR-498, non-targeting control or no miRNA inhibitor. Full-length BRCA1 was detected 
using a monoclonal anti-BRCA1 antibody (Calbiochem, #OP92) and HSC70/HSP70 served as a loading 
control. C) Relative mRNA levels of BRCA1 after transfection of MCF7 cells with pre-miR-498, pre-
miR-146a-5p, non-targeting control or no miRNA precursor. Error bars represent standard deviation 
for triplicates of one representative experiment. * p<0.05.  
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4.5. Inhibition of miR-498 reduces proliferation in triple negative breast 
cancer cells  
To gain more insight into the biological effect of miR-498 on breast tumorigenesis and 
given that BRCA1 is presumed to have a growth suppressor function (Holt et al., 1996; 
Thompson et al., 1995), we transfected HS578T cells, which previously showed elevated 
levels of miR-498, with anti-miR-498 or mock and analyzed the cell growth by WST-1 cell 
viability assay. Figure 21 shows that inhibition of miR-498 resulted in reduced proliferation 
in comparison to mock transfected cells. These results indicate that down-regulation of 
BRCA1 by miR-498 can promote proliferation and contribute to tumorigenesis. 
 
 
Figure 21. Effect of miR-498 inhibition on proliferation of HS578T cells. WST-1 cell viability assay was 
performed at 24, 48, 72, 96, 120 and 144 hours after transfection of HS578T cells with anti-miR-498 
or mock transfected. 
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1. MICRORNA DEREGULATION IN BREAST CANCER MOLECULAR 
SUBTYPES 
Breast cancer is a highly heterogeneous disease. In the past few years, gene expression 
profiling has identified at least four major subtypes (luminal A, luminal B, Her2 and triple 
negative) with distinct biological features, clinical outcomes and responses to therapies 
(Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 2003). As a consequence of this 
subclassification, a number of therapies that target specific molecules involved in cancer 
progression have been developed, improving survival of patients. Nevertheless, although 
breast cancer-related genes have been extensively investigated, little is known about the 
role of miRNAs in breast cancer molecular subtypes. In a preliminary study, Blenkiron and 
colleagues (Blenkiron et al., 2007) showed that miRNAs might contribute to the stratification 
of breast tumors into the intrinsic subtypes. Since miRNAs are key regulators of many 
cellular processes, identification of subtype-specific miRNAs would provide better 
understanding of the biology of these tumors, especially in the case of triple negative 
cancers, which are associated with the most aggressive clinical behavior and do not respond 
to current targeted therapies. By analyzing the expression levels of 1919 human miRNAs in a 
large series of breast tumors and normal breast tissues, we aimed to find miRNAs associated 
with breast cancer and identify those miRNAs specifically deregulated in breast cancer 
molecular subtypes. 
1.1. MiRNA expression profiling differentiates breast tumors from normal 
breast tissues although stratification of molecular subtypes is imperfect 
We first performed unsupervised hierarchical clustering of our samples and observed a 
clear separation between breast tumors and normal breast tissues, thus confirming previous 
studies that suggest that miRNA expression profiling can be used to classify breast tissues 
(Iorio et al., 2005; Lu et al., 2005). We detected common expression profiles in tumors 
having the same molecular subtype, but also clusters of samples belonging to different 
subtypes (Figure 8). One possible explanation could be that miRNAs are regulating multiple 
processes in the cell and our samples could be grouping not exclusively according to their 
molecular subtype but to other tumor characteristics. Interestingly, Rothé et al. came to the 
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same conclusion after comparing clustering of breast tumors based on miRNA and mRNA 
expression profiles (Rothe et al., 2011). For instance, it has been suggested that miRNA 
expression profiles may discriminate tumors of breast cancer patients with different 
prognosis (Perez-Rivas et al., 2014) and could predict BRCA mutation status in hereditary 
tumors (Tanic et al., 2015). Therefore, miRNAs may offer additional information on breast 
tumors stratification. Another explanation to our imperfect unsupervised cluster could be 
the stratification of breast tumors into new molecular entities. The integration of DNA copy 
number alterations, DNA methylation, exome sequencing and mRNA, miRNA and protein 
expression has led to the identification of novel subtypes with characteristic alterations 
(Curtis et al., 2012b; Network, 2012; Prat et al., 2010). New subtypes could be also present 
in our samples, making it difficult the stratification into the four classical subtypes. Further 
studies are needed in order to obtain a comprehensive picture of breast cancer 
heterogeneity that would allow improvements in the clinical management of the patients. 
1.2. MiRNAs commonly and specifically deregulated in breast cancer 
molecular subtypes 
In order to identify miRNAs associated with breast tumors and the intrinsic subtypes, 
we performed a supervised analysis. The large amount of deregulated miRNAs identified in 
our set of breast tumors highlights the important role that miRNAs play in breast 
tumorigenesis. Among the most deregulated miRNAs, miR-125b-5p and miR-21-5p have 
been repeatedly associated with breast cancer (Iorio et al., 2005; Volinia et al., 2006). MiR-
21-5p is known to function as an oncogene by targeting tumor suppressor genes including 
tropomyosin 1 (TPM1), programmed cell death 4 (PDCD4) and phosphatase and tensin 
homolog (PTEN), leading to cell proliferation and inhibition of apoptosis and regulating 
cancer invasion and metastasis in breast cancer (Frankel et al., 2008; Huang et al., 2009; Zhu 
et al., 2007). MiR-125b-5p is upregulated in many cancers but downregulated in others such 
as breast cancer, and controls many different cellular processes by targeting numerous 
transcription factors such as ETS1, E2F3 and BCL3 (Guan et al., 2011; Huang et al., 2011; 
Zhang et al., 2011). We found that both miR-21 and miR-125b were deregulated through all 
the molecular subtypes, underlying their essential role in breast cancer. In addition and due 
to the large number of miRNAs analyzed in the present study, we have identified new 
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miRNAs that have not been associated with breast cancer before, expanding the knowledge 
on miRNA deregulation in breast cancer. Some of the most significant ones are deregulated 
through all the molecular subtypes, like miR-3613-3p, miR-4668-5p, miR-4516, miR-548as-
3p, miR-4488, miR-3656 and miR-5704, making them ideal candidates for breast cancer 
detection. 
Even though several studies have focused on the identification of miRNAs associated 
with breast cancer, little is known about deregulated miRNAs in breast cancer molecular 
subtypes. By analyzing the expression of 309 human miRNAs, Blenkiron and colleagues 
detected some miRNAs differentially expressed among the intrinsic subtypes (Blenkiron et 
al., 2007). In the present study, we analyzed the expression of 1919 human miRNAs and 
consequently identified a larger number of miRNAs associated with tumor subtypes (Figure 
9). Interestingly, comparison of our results with the ones obtained by Blenkiron et al. 
revealed similar patterns of expression for several key miRNAs (Figure 22). Of note, all these 
miRNAs seem to be associated with ER status. For example, miR-150, miR-155 and miR-187 
are upregulated in triple negative and Her2 tumors when compared with luminal samples, 
while miR-145, miR-199a, miR-30a, let-7a, let-7b, let-7c, let-7f and miR-342 are 
downregulated in triple negative and Her2 samples when compared with luminal tumors. 
These results are consistent with previous studies that suggest that the expression levels of 
miR-155 are inversely correlated with ER (Lu et al., 2012) while the expression of miR-342 is 
higher in ER positive tumors compared with triple negative tumors (Lowery et al., 2009). In 
addition, overexpression of miR-150 and miR-155 and downregulation of miR-145, miR-30a 
and members of the let-7 family has been associated with breast cancer progression, tumor 
aggressiveness, self-renewal and loss of differentiation (Bussing et al., 2008; Chen et al., 
2012; Cheng et al., 2012; Huang et al., 2013; Zou et al., 2012), thus explaining the 
differences observed between luminal and non-luminal tumors. 
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Figure 22. miRNAs associated with breast cancer molecular subtypes in the study carried out by 
Blenkiron et al. that have a similar pattern of expression in the present study. Colors represent the 
average expression value for each group of interest: dark red indicates high expression and dark 
grey, low expression. 
 
To our knowledge, this is the first report that takes into account the miRNA expression 
profile of normal tissues to obtain miRNAs associated with breast cancer intrinsic subtypes. 
We believe that this approach might be more appropriate for the identification of 
specifically deregulated miRNAs. For example, we found that miR-342 is downregulated in 
triple negative and Her2 when compared with luminal tumors, as previous studies have 
suggested (Blenkiron et al., 2007; Lowery et al., 2009). However, all the subtypes showed 
overexpression of this miRNA when compared with the normal tissues, suggesting that the 
upregulation of this miRNA might play a general role in breast tumorigenesis and could not 
be specific to ER positive tumors.  
Interestingly, we could only identify one specific miRNA for Her2 tumors (Figure 9B). 
These results are in accordance with the ones obtained by van Schooneveld et al. (van 
Schooneveld et al., 2012). After comparing miRNA expression profiles of tumor subtypes, 
they could not find any specific miRNA for Her2 tumors while identified triple negative 
subtype as the subgroup with more specific miRNAs. These findings suggest that Her2 
subtype might enclose tumors with diverse miRNA profiles, making it difficult the 
identification of exclusive miRNAs. In fact, when compared with the normal tissues, Her2 
was the subtype with less differentially expressed miRNAs, highlighting its heterogeneous 
miRNA profile. On the other hand, a great number of specifically deregulated miRNAs were 
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identified for triple negative tumors, including several members of the let-7 family (let-7d-
5p, let-7i-5p, let-7a-5p, let-7d-3p). Let-7 is a family of miRNAs highly conserved across 
species and is often cited as the archetypal tumor-suppressing miRNA family. It has been 
shown that downregulation of let-7 promotes self-renewal and leads to a less differentiated 
cellular state in human and murine breast cells (Ibarra et al., 2007; Yu et al., 2007). Thus, 
misregulation of member of this family in triple negative breast tumors could explain at 
least in part why this subtype tends to grow and spread more quickly than other types of 
breast cancer and why triple negative cancer cells are often poorly differentiated. 
1.3. miRNA signatures predict breast cancer molecular subtypes  
Machine learning is a promising tool in disease diagnosis since it allows the recognition 
of expression patterns in groups of samples and the use of these patterns for the 
classification of new samples. In fact, several prognostic classifiers are currently used as 
treatment decision tools. The 70-gene predictor Mammaprint (Glas et al., 2006) and the 21-
gene signature Oncotype (Paik et al., 2004) predict risk of recurrence in early-stage breast 
cancer patients and inform the utility of chemotherapy as part of the treatment plan. By 
using support vector machines, we have generated five microarray classifiers that 
discriminate breast tumors and breast cancer molecular subtypes with high sensitivity and 
specificity (Table 8). The accuracy for our classifiers is in the range 0.97-0.98, suggesting 
excellent classification ability. These classifiers have been validated in an independent set of 
samples with similar sensitivity and specificity, confirming the potential of these miRNAs to 
stratify breast tumors. Since inmunohistochemical (IHC) tests can be limited by their need of 
well-preserved tissues and the subjective interpretation of stain intensity by pathologists 
(Dunstan et al., 2011), we consider that the microarray classifiers reported here could be 
useful tools to complement IHC tests for breast cancer classification. MiRNAs have been 
shown to be unusually well-preserved in a range of specimen types and are ideal substrates 
for the molecular characterization of FFPE tissues due to their small size and resistance to 
degradation (Liu et al., 2009). Nevertheless, since reproducibility is a major criticism about 
microarray technology, validation in a prospective multicenter trial is required before any 
translational application.  
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The signatures generated here include miRNAs that have previously been associated 
with breast cancer and other cancers, and that are implicated in the regulation of cellular 
processes such as proliferation, migration, invasion and apoptosis. The pathways predicted 
to be significantly enriched for each signature are closely related to cancer development 
and progression, suggesting that the identified miRNAs are biologically relevant and their 
choice is not arbitrary. The Cancer Genome Atlas Network has recently shown that somatic 
mutations in PIK3CA, TP53, MAP3K1 and MAP2K4 genes occur at high incidence across 
breast cancer molecular subtypes (Cancer Genome Atlas, 2012). Interestingly, PI3K-AKT, P53 
and MAPK signaling pathways are predicted to be associated with the identified signatures 
with high statistical significance, which suggests that deregulation of these miRNAs might 
contribute to the alteration of these pathways in breast cancer. 
Some of the miRNAs that compose each signature have previously been associated with 
the corresponding intrinsic subtype, thus confirming the utility of these signatures in the 
prediction of breast cancer molecular subtypes. For example, reduced levels of miR-29c has 
been found in basal-like cancers when compared with other subtypes (Sandhu et al., 2014); 
a lower expression of miR-205 is associated with HER2 breast tumors (Mattie et al., 2006) 
and interestingly, miR-205 has been reported to regulate Her3 in human breast cancer (Iorio 
et al., 2009) and, in turn, to be regulated by Her2 (Adachi et al., 2011); miR-221 increases 
proliferation in ER-positive cells (Di Leva et al., 2010); and miR-22 is a suppressor of ER alpha 
and is downregulated in ER-positive breast cancer cells and clinical samples (Xiong et al., 
2010). Consequently, we hypothesize that the identified miRNA signatures could be 
informative for breast cancer diagnosis and might assist in defining specific targets for 
future therapy. 
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2. CIRCULATING MICRORNAs AS EARLY DETECTION MARKERS 
FOR BREAST CANCER 
Despite improvements in screening techniques and treatment strategies, breast cancer 
is still one of the leading causes of cancer death among women (Ferlay et al., 2015), mainly 
due to late stage at initial diagnosis. Thus, efficient diagnostic tools are urgently needed to 
improve early breast cancer detection and consequently patient outcome. Even though 
mammography is the most reliable way to detect breast cancer, it has some limitations 
including low sensitivity in dense breasts, severe pain caused to some women  or radiation 
risk, especially for women below age 35 (Kolb et al., 2002; Law and Faulkner, 2001; Sharp et 
al., 2003). Biopsy is the method used to establish a definitive diagnosis but it is an invasive 
procedure. Serum tumor markers such as CEA or CA 15-3, although being promising at the 
time of their identification, are not recommended by the ASCO and other expert panels for 
screening or diagnosis of breast cancer due to their low sensitivity in early stages of the 
disease (Harris et al., 2007). Consequently, there is an urgent need for the identification of 
sensitive, specific and non-invasive markers for early breast cancer detection. Given the 
important role that microRNAs play in tumorigenesis and their remarkable stability in body 
fluids, we have evaluated their potential as novel non-invasive breast cancer biomarkers by 
analyzing two independent series of plasma. 
2.1. Comparison of miRNA expression between tumor and plasma 
In the first part of this thesis, we have identified a large number of miRNAs deregulated 
in breast tumors when compared with normal breast tissues. Since these miRNAs might be 
relevant for breast cancer detection, we decided to investigate the expression of the most 
relevant ones in plasma. First, we validated their deregulation in tumors by qRT-PCR. A 
strong correspondence between microarray expression and qRT-PCR was observed, as 91% 
of the explored miRNAs were validated (p-value<0.05). These results are in line with those 
reported by Git et al., where a high correlation (0.82-0.92) between Exiqon platform and 
qPCR was described (Git et al., 2010). However, the validation of significant tumoral miRNAs 
in plasma was more controversial. Among 10 miRNAs analyzed in the discovery set, 5 were 
found differentially expressed in the plasma of breast cancer patients when compared with 
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healthy women and one showed a trend. However, only half of these six miRNAs were 
deregulated in the same direction as in tumors (miR-21-5, miR-142-3p and miR-96-5p). 
Dissimilar patterns of miRNA expression between tumor and plasma have been reported 
recently. Chan et al. performed miRNA profiling of tumors and sera from breast cancer 
patients and healthy individuals and observed 73 miRNAs deregulated in breast tumors and 
85 in plasma. However, only 21 were in common in both tissues, and 13 of them were 
deregulated in opposite directions (Chan et al., 2013). Similarly, Pigati et al. studied the 
liberation of miRNAs from malignant and non-malignant mammary cells into body fluids and 
suggested that miRNAs are released from breast cancer cells in a selective manner and 
therefore, extracellular and cellular miRNA profiles are different (Pigati et al., 2010).  
2.2. miR-505-5p, miR-96-5p, miR-125b-5p and miR-21-5p are deregulated in 
tumors and plasma of breast cancer patients  
Validation in a second series of plasma led to the confirmation that miR-505-5p, miR-
125b-5p, miR-21-5p and miR-96-5p are overexpressed in the plasma of breast cancer 
patients. Since these miRNAs are significantly deregulated both in tumor and plasma from 
pretreated breast cancer patients, we hypothesize that miR-505-5p, miR-125b-5p, miR-21-
5p and miR-96-5p might be candidates for non-invasive breast cancer detection. 
Overexpression of circulating miR-21-5p has been described in breast cancer patients (Asaga 
et al., 2011; Mar-Aguilar et al., 2013; Ng et al., 2013; Si et al., 2013) but also in other cancers 
such as esophageal, gastric, colorectal and lung (Du et al., 2014; Wang and Zhang, 2012; 
Zheng et al., 2011). These findings show the potential utility of circulating miR-21-5p as a 
broad-spectrum biomarker for the detection of various cancers and not specifically for 
breast cancer diagnosis. Mir-125b-5p has also been reported to be upregulated in the serum 
of breast cancer patients (Mar-Aguilar et al., 2013; Wang et al., 2012) and has been 
associated with chemotherapeutic resistance, with non-responsive patients having higher 
expression levels (Wang et al., 2012). To the best of our knowledge, this is the first report of 
circulating miR-505-5p and miR-96-5p being associated with breast cancer. Nevertheless, 
downregulation of miR-505 and upregulation of miR-96-5p have been reported in breast 
tumors and have been related to increased cell proliferation (Li et al., 2014; Yamamoto et 
al., 2011). 
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 ROC curve analysis showed that the discrimination potential of these four miRNAs was 
acceptable, with AUC ranging from 0.6070 to 0.7213, being miR-505 and miR-96-5p the 
most valuable biomarkers for discriminating breast cancer patients from healthy individuals. 
In addition, the levels of miR-505-5p and miR-21-5p were significantly reduced after 
surgery/treatment, suggesting that the expression of these two miRNAs is dependent on 
tumor dynamics. Although quantification of levels of miR-505-5p and miR-21-5p in the same 
cohort of patients is required, the reduction of expression in the postreated group indicates 
the potential utility of these miRNAs to monitor treatment response and highlights their 
clinical value for breast cancer detection and surveillance.  
Moreover, we found significant higher levels of circulating miR-505 in patients with 
luminal low-grade tumors, suggesting that this miRNA could be used not only in the 
detection and surveillance of breast cancer but also in the recognition of luminal subtypes. 
Similar to other studies (Asaga et al., 2011; Wang and Zhang, 2012), circulating miR-21 did 
not show any association with age of the patient, tumor size, grade, lymph node, ER, PR and 
Her2 status, ki-67 levels and molecular subtype. Contrarily, other reports have shown an 
association with larger tumor size and lymph node metastasis (Si et al., 2013). Although 
higher expression levels of circulating miR-125b have been related to higher tumor grade 
and lymph node metastasis (Wang et al., 2012), we did not observed any association with 
these factors. In order to use circulating miRNAs as a liquid biopsy, further studies with 
larger cohorts of patients are required to elucidate the relationship between miRNA 
expression levels and clinicopathologic features of breast cancer patients. 
In conclusion, we have reported and validated the overexpression of miR-505-5p, miR-
125b-5p, miR-21-5p and miR-96-5p in the plasma of breast cancer patients and 
demonstrated the potential utility of these miRNAs as non-invasive biomarkers for breast 
cancer screening. A great advantage of our study is that most of the patients had an early 
stage breast cancer at the time of blood sample collection, which highlights the relevance of 
the identified miRNAs in early breast cancer detection. Although promising, prospective 
studies on larger cohorts of patients are required to confirm the diagnostic value of these 
miRNAs.  
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3. MICRORNAs ASSOCIATED WITH RECURRENCE-FREE SURVIVAL 
IN TRIPLE NEGATIVE BREAST CANCER 
Triple negative tumors are associated with the most aggressive clinical behavior and 
poorest prognosis in breast cancer (Dent et al., 2007). Due to the lack of therapeutic targets, 
chemotherapy is the only possibility for triple negative patients, but although some patients 
have an excellent response, others experience early disease recurrence in the first 3-5 years 
following diagnosis (Liedtke et al., 2008; Mulligan et al., 2008). During the last decade, 
several gene expression signatures for outcome prediction have been described and 
validated in breast cancer with consistent results (Glas et al., 2006; Paik et al., 2004). 
However, these assays are not useful in ER-negative disease (Fan et al., 2011) and therefore, 
identification of robust prognostic and predictive markers in triple negative patients is 
urgently needed. In this context, we used miRNA expression profiling to find miRNAs that 
can distinguish groups of triple negative patients with different clinical outcomes.  
3.1. Deregulated miRNAs in node-positive triple negative patients with 
different outcome 
While women with node-negative triple negative tumors generally have an excellent 
five-year disease-free survival when treated, the presence of any lymph node metastases at 
the time of diagnosis is a negative prognostic indicator (Hernandez-Aya et al.; Rakha et al., 
2007). In accordance to these data, we found that most node-negative women in our two 
cohorts of triple negative patients survived after 5 years of diagnosis but only 40% of node-
positive women had no disease recurrence at the end of this period. In order to identify 
miRNAs that can distinguish node-positive patients with different outcome, the expression 
of 1919 human miRNAs was analyzed by microarray technology in 10 node-positive triple 
negative patients. Among the 17 miRNAs identified, only two (let-7i-5p and let-7a-5p) were 
specific of triple negative subtype, suggesting that most of the miRNAs involved in the 
aggressiveness of triple negative tumors are not subtype specific. The miRNAs identified 
showed significant lower expression in patients with shorter RFS, indicating that the 
expression of these miRNAs might be lost in highly aggressive triple negative tumors. In fact, 
most of these miRNAs have been reported to act as cancer suppressor genes by inhibiting 
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cell migration, invasion and proliferation. Similarly, Avery-Kiejda et al. suggested that miRNA 
expression profiles tend to be downregulated in node-positive triple negative patients while 
are overexpressed in node-negative disease (Avery-Kiejda et al., 2014).  Interestingly, many 
of the identified miRNAs belong to a miRNA cluster, such as miR-23b/27b/24-1 cluster in 
chromosome 9, miR-23a/24-2/27a cluster in chromosome 19 and let-7a/7b cluster in 
chromosome 22. Since it has been shown that clustered miRNAs have a tendency to 
coordinately regulate target genes (Grun et al., 2005; Hausser and Zavolan, 2014), 
deregulation of these miRNAs might have an additive effect in the same molecular pathway. 
Surprisingly and contrarily to what has been published before in breast cancer (Yan et al., 
2008), miR-21 was found underexpressed in patients with worse prognosis. Although 
further investigation is required, a different role of miR-21 in triple negative disease could 
be the explanation for this finding. 
3.2. MiR-30c-5p and miR-195-5p are associated with recurrence in triple 
negative breast cancer 
We found that decreased expression levels of let-7b-5p, miR-195-5p, miR-24-3p and 
miR-30c-5p were significantly associated with increased risk of recurrence of node-positive 
TNBC patients. However, validation by qRT-PCR in a larger cohort of patients confirmed the 
prognostic value of only miR-30c-5p and miR-195-5p in both node-positive and the whole 
group of triple negative patients. Moreover, the stratification of the patients according to 
the combination of both miRNAs resulted in a great separation of high- and low-risk groups. 
Interestingly, the pathway enrichment analysis suggested that these miRNAs seem to 
collectively target a broad range of signaling pathways related to proliferation, invasion and 
cell cycle regulation. 
It has been suggested that miR-195-5p acts as a tumor suppressor gene, the expression 
of which is downregulated in breast cancer (Li et al., 2011). More importantly, its 
overexpression in breast cancer cells inhibits cell proliferation, reduces cell colony 
formation, suppresses cell migration and promotes apoptosis through inhibition of RAF-1 
and cyclins E1 (CCNE1) and D1 (CCND1) (Li et al., 2011; Luo et al., 2014; Yang et al., 2013). 
Furthermore, the expression of miR-195-5p has recently been associated with sensitivity to 
the anthracycline drug Adriamycin (also known as Doxorubicin), and it has been shown that 
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multidrug-resistant breast cancer tissues have low levels of this miRNA (Yang et al., 2013). 
Likewise, miR-30c-5p has been reported to regulate invasion and proliferation in breast 
cancer cells by targeting the oncogene KRAS and the cytoskeleton network genes encoding 
twinfilin 1 (TWF1) and vimentin (VIM) (Bockhorn et al., 2013; Tanic et al., 2012). Moreover, 
miR-30c-5p has lately been shown to be downregulated in Doxorubicin-resistant breast 
cancer cell lines and its overexpression sensitivizes tumor cells to Doxorubicin by inhibiting 
the anti-apoptotic gene YWHAZ (Fang et al., 2014).    
Of note, miR-195-5p exhibited association with poor prognosis even after adjustment 
for relevant clinical variables, indicating that this miRNA might be an independent 
prognostic marker in TNBC. Although preliminary, the association of miR-195-5p with 
disease recurrence could potentially serve to define a group of triple negative patients who 
may benefit from a more aggressive therapy. On the other hand, we found that the 
expression of miR-30c-5p seems to be associated with tumor size in triple negative patients. 
Similarly, Tanic et al. showed that the overexpression of miR-30c-5p in the TNBC cell line 
MDA-MB-436 reduces KRAS levels and inhibits proliferation (Tanic et al., 2012). Hence, 
tumors that express low levels of miR-30c-5p might proliferate more and increase in size. 
Furthermore and taking into consideration the association of both miRNAs with Doxorubicin 
sensitivity (Fang et al., 2014; Yang et al., 2013), therapeutic delivery of miR-195-5p and miR-
30c-5p could improve chemotherapy response in triple negative patients with low levels of 
these miRNAs. Although our results may require further external validation in a larger 
cohort, the prognostic and predictive value of these two miRNAs in TNBC is promising. 
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4. MiR-498 REGULATES BRCA1 EXPRESSION IN SPORADIC TRIPLE 
NEGATIVE BREAST CANCER 
In early 1990s, family-based linkage analysis and positional cloning led to the 
identification of high-penetrance genes BRCA1 (Miki et al., 1994) and BRCA2 (Wooster et al., 
1994), two tumor-suppressor genes that are frequently mutated in hereditary breast 
cancers. During the past two decades, BRCA1 has been found to play a critical role in various 
cellular processes, including DNA repair by distinct pathways, cell cycle checkpoints control, 
centrosome amplification, transcriptional activation of target genes, and ubiquitin ligation 
(Drost and Jonkers, 2014; Narod and Foulkes, 2004). While the specific functions of BRCA1 
are still being elucidated, it is clear that functional BRCA1 protein is required to prevent 
breast transformation (Xu et al., 1999). Although sporadic triple negative tumors share 
many characteristics with BRCA1-germline mutated breast tumors, they usually do not 
present somatic mutations in the BRCA1 gene. However, several studies have shown that 
most sporadic triple negative tumors have a reduced expression of the BRCA1 gene (Mueller 
and Roskelley, 2003; Turner et al., 2007), which suggests a possible role of BRCA1 
dysfunction in the pathogenesis of sporadic triple negative breast cancer. Taking into 
consideration that miRNAs function as negative regulators of gene expression, we 
investigated their possible involvement in the inactivation of BRCA1 in sporadic triple 
negative tumors. 
4.1. BRCA1 is a target of miR-498 and miR-187-5p  
In the first part of this thesis, we identified 78 miRNAs that were overexpressed in 
sporadic triple negative tumors but not in other breast cancer subtypes when compared 
with normal breast tissues. Since reduced expression of BRCA1 in triple negative tumors 
could be produced by high levels of a miRNA targeting this gene, we investigated if these 
miRNAs have binding sites in the 3’UTR of BRCA1. At least two bioinformatics algorithms 
predicted with high scores that miR-498 and miR-187-5p bind to the 3'UTR of the BRCA1 
gene, and we functionally validated these results by luciferase reporter assay. In addition, 
we have confirmed with similar levels of repression, previous studies that report that miR-
146a targets BRCA1 3’UTR (Garcia et al., 2011; Shen et al., 2008).  
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The role of miR-498 in cancer development has not been well documented. While it 
seems to be dowregulated in some cancers such as colon and ovarian cancer (Gopalan et al., 
2015; Kasiappan et al., 2012), its overexpression has been reported in metastatic medullary 
thyroid carcinoma and retinoblastoma (Santarpia et al., 2013; Zhao et al., 2009). Regarding 
its targets, miR-498 has been shown to bind to the 3’UTR of HER2 and TERT (Kasiappan et 
al., 2012; Leivonen et al., 2014), but reports showing targeting of BRCA1 have not been 
described so far. Similarly, high levels of miR-187-5p have been associated with ovarian 
cancer (Chao et al., 2012) but its downregulation has been reported in clear cell renal cell 
carcinoma and prostate cancer (Fuse et al., 2012; Zhao et al., 2013). Interestingly, its 
overexpression has been associated with poor outcome in breast cancer, leading to a more 
aggressive phenotype (Mulrane et al., 2012). These findings suggest that miR-498 and miR-
187-5p might act as oncogenes or tumor suppressors depending on the cellular context, as it 
happens with other miRNAs such as miR-125b-5p. 
4.2. MiR-498 regulates BRCA1 expression in breast cancer cell lines 
After analyzing the expression of miR-498 and miR-187-5p in breast cancer cell lines of 
different subtypes, we found that miR-498 was overexpressed in the triple negative cell line 
HS578T while miR-187-5p seemed to be overexpressed in the luminal cell lines BT474 and 
MCF7. Since we were interested in miRNAs with increased expression levels in triple 
negative cell lines and negatively correlated with BRCA1 expression levels, we decided to 
focus on miR-498 for following experiments. We functionally demonstrated the interaction 
between miR-498 and BRCA1 in breast cancer cell lines: inhibition of miR-498 in HS578T cell 
line increased BRCA1 levels and its overexpression in MCF7 cell line reduced BRCA1 
expression. These results suggest that miR-498 regulates BRCA1 expression in breast cancer 
and its overexpression could contribute to the pathogenesis of sporadic TNBC via BRCA1 
downregulation. These findings confirm previous studies that suggest that miRNA 
deregulation might be involved in the inactivation of BRCA1 in sporadic breast cancer 
(Garcia et al., 2011; He et al., 2014; Moskwa et al., 2011; Tan et al., 2014).  
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4.3. MiR-498 plays a role in triple negative breast cancer cell proliferation  
In addition, we have demonstrated that miR-498 inhibition leads to reduced 
proliferation of triple negative breast cancer cells. Our findings are consistent with a role of 
miR-498 in the regulation of BRCA1, since induction of BRCA1 expression has been shown to 
inhibit growth in breast tumors and cell lines (Holt et al., 1996). Hence, our data support 
that miR-498 promotes cell proliferation in triple negative breast cancer through direct 
regulation of BRCA1 expression. Although the effect of miR-498 deregulation on DNA repair 
needs to be investigated, the findings reported here have potential clinical implications. The 
most relevant one is that tumors with high levels of miR-498 might be more sensitive to 
PARP inhibitors and DNA damaging chemotherapeutic agents. Therefore, the monitoring of 
miR-498 expression could serve to identify a group of breast cancer patients that may 
benefit from these therapies.  
In conclusion, this study sheds light on the mechanisms behind the decreased 
expression of BRCA1 in sporadic TNBC. Determination of these mechanisms is essential to 
increase our understanding of triple negative breast cancer etiology and to permit better 
therapeutic approaches. 
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CONCLUSIONS 
 
1. We have defined five miRNA signatures that discriminate breast tumors and the 
main breast cancer molecular subtypes with high sensitivity and specificity. Pathway 
enrichment analysis indicates that these miRNAs might regulate different biological 
processes related to cancer development and progression.  
 
2. Comparison of miRNA expression between tumor and plasma showed dissimilar 
patterns of expression for some miRNAs, which could indicate a selective release 
from breast cancer cells into the blood. We have reported and validated the 
overexpression of miR-505-5p, miR-125b-5p, miR-21-5p and miR-96-5p in the plasma 
of breast cancer patients when compared with healthy women and demonstrated 
the potential utility of these miRNAs as non-invasive biomarkers for early breast 
cancer detection.  
 
3. We have identified a set of 17 miRNAs that are downregulated in breast tumors of 
node-positive triple-negative patients with poor outcome. Moreover, we found that 
miR-30c-5p and miR-195-5p are associated with recurrence in triple negative breast 
cancer, and that miR-195-5p might be an independent prognostic marker that could 
serve to define a group of triple negative patients who may benefit from a more 
aggressive therapy. 
 
4. Two triple-negative specific miRNAs, miR-498 and miR-187-5p, were found to target 
BRCA1 3’UTR. We demonstrated that miR-498 regulates BRCA1 expression in breast 
cancer cell lines and its inhibition leads to reduced proliferation in triple negative 
breast cancer cells. Our results shed light on the mechanisms behind the decreased 
expression of BRCA1 in sporadic triple negative breast cancer. 
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CONCLUSIONES 
 
1. Hemos definido cinco firmas de miRNAs que discriminan los tumores de mama y los 
principales subtipos moleculares de cáncer de mama con gran sensibilidad y 
especificidad. El análisis de enriquecimiento funcional indica que estos miRNAs 
podrían estar regulando distintos procesos biológicos relacionados con el desarrollo 
y la progresión del cáncer.  
 
2. La comparación de la expresión de ciertos miRNAs en tumores y plasma mostró 
patrones de expresión diferentes para algunos miRNAs, lo que podría indicar que 
existe una liberación selectiva por parte de las células cancerosas a la sangre. Hemos 
validado la sobreexpresión de los miR-505-5p, miR-125b-5p, miR-21-5p y miR-96-5p 
en el plasma de pacientes con cáncer de mama en comparación con mujeres sanas, y 
hemos demostrado la posible utilidad de estos miRNAs como biomarcadores no 
invasivos para la detección temprana del cáncer de mama.  
 
3. Hemos identificado un grupo de 17 miRNAs que están infraexpresados en tumores 
de mama de pacientes triple negativas con ganglios positivos y mal pronóstico. 
Además, hemos encontrado que los miR-30c-5p y miR-195-5p están asociados con 
recurrencia y que el miR-195-5p podría ser un marcador de pronóstico 
independiente en cáncer de mama triple negativo. El análisis de la expresión del 
miR-195-5p en tumores podría servir para definir un grupo de pacientes triple 
negativas que podrían beneficiarse de una terapia más agresiva. 
 
4. Hemos encontrado que dos miRNAs específicos de tumores triple negativos, miR-498 
y miR-187-5p, tienen como diana la región 3’UTR de BRCA1. Además, hemos 
demostrado que el miR-498 regula la expresión de BRCA1 en líneas celulares de 
cáncer de mama, y que su inhibición da lugar a una reducción en la proliferación de 
las células triple negativas. Estos resultados podrían explicar la disminución en la 
expresión de BRCA1 que se observa en cáncer de mama esporádico triple negativo. 
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Supplementary Table S1. Specifically up or downregulated miRNAs in breast cancer molecular 
subtypes after comparison with normal breast tissues. 
Molecular 
subtype 
Deregu 
lation 
Number miRNAs 
Triple 
negative 
Up 78 miR-642b-5p,miR-4795-3p,miR-4653-3p,miR-3124-3p,miR-
4501,miR-4698,miR-1973,miR-3976,miR-4417,miR-634,miR-
4723-5p,miR-150-5p,miR-4639-3p,miR-659-5p,miR-4633-5p,miR-
5584-3p,miR-4449,miR-921,miR-5000-3p,miR-4707-3p,miR-513a-
5p,miR-519e-5p,miR-552,miR-4431,miR-4677-3p,miR-4329,miR-
1273e,miR-711,miR-4503,miR-3687,miR-492,miR-3591-5p,miR-
5588-3p,miR-874,miR-181a-2-3p,miR-4636,miR-498,miR-4782-
5p,miR-490-5p,miR-548ao-3p,miR-5193,miR-3648,miR-4511,miR-
1827,miR-187-5p,miR-550b-2-5p,miR-4674,miR-3912,let-7d-
3p,miR-2113,miR-4264,miR-675-3p,miR-5689,miR-4784,miR-
1285-5p,miR-4694-5p,miR-5089,miR-5187-5p,miR-650,miR-506-
5p,miR-891a,miR-1265,miR-1197,miR-3944-5p,miR-4683,miR-
4536-3p,miR-3618,miR-4535,miR-4778-5p,miR-3925-5p,miR-
1321,miR-4436b-5p,miR-3161,miR-5006-3p,miR-3606,miR-146a-
5p,miR-5580-5p 
Down 27 miR-554,miR-4444,miR-629-5p,miR-10a-5p,miR-140-3p,miR-
374a-5p,miR-124-5p,let-7d-5p,miR-4791,miR-548o-3p,miR-
1202,miR-4328,miR-448,miR-382-3p,miR-29b-2-5p,miR-590-
3p,miR-10b-5p,let-7i-5p,miR-4301,miR-126-3p,miR-199a-5p,miR-
3607-3p,miR-214-3p,miR-491-3p,miR-4285,miR-5701,let-7a-5p 
Her2 Up 0 - 
Down 1 miR-574-3p 
Luminal B Up 23 miR-16-5p,let-7g-5p,miR-23a-3p,miR-200c-3p,miR-34a-5p,miR-
101-3p,miR-26b-5p,miR-193a-3p,miR-30b-5p,miR-20a-5p,miR-
29a-3p,miR-15a-5p,miR-27b-3p,miR-93-5p,miR-4714-5p,miR-
1280,miR-29b-3p,miR-15b-5p,miR-26a-5p,miR-374b-5p,miR-
429,miR-107 
Down 16 miR-184,miR-4462,miR-4649-5p,miR-1299,miR-4433-3p,miR-
4472,miR-302a-3p,miR-4507,miR-3646,miR-371b-5p,miR-
4497,miR-4787-5p,miR-548ap-5p,miR-548j,miR-3940-5p,miR-
4505,miR-1275 
Luminal A Up 5 miR-4421,miR-3667-5p,miR-5196-3p,miR-548k,miR-331-3p 
Down 12 miR-486-5p,miR-4492,miR-664-3p,miR-124-3p,miR-4446-5p,miR-
3664-5p,miR-513b,miR-3620,miR-4769-3p,miR-4646-3p,miR-
3182,miR-4723-3p 
Common Up 25 miR-21-5p,miR-3613-3p,miR-4668-5p,miR-106b-5p,miR-200a-
3p,miR-5704,miR-1278,miR-182-5p,miR-1264,miR-96-5p,miR-
190b,miR-3611,miR-185-5p,miR-339-5p,miR-7-5p,miR-340-
5p,miR-203,miR-342-5p,miR-1244,miR-600,miR-760,miR-92a-2-
5p,miR-219-2-3p,miR-553,miR-4521 
Down 27 miR-889,miR-192-3p,miR-432-5p,miR-1224-5p,miR-1205,miR-
1228-5p,miR-571,miR-1229,miR-4253,miR-2276,miR-577,miR-
548s,miR-744-3p,miR-1207-5p,miR-1270,miR-877-5p,miR-499a-
5p,miR-574-5p,miR-718,miR-4695-3p,miR-3164,miR-3148,miR-
3941,miR-4488,miR-4516,miR-3656,miR-125b-5p 
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Supplementary Table S2. Comparison of the performance of different algorithms used for the 
classification of breast tumors and the different molecular subtypes.  
Classifier Algorithm Accuracy MCC RMSE AUC miRNAs 
Breast tumors 
vs normal 
breast tissues 
KNN 0.95 0.74 0.18 0.91 25 
 SVM 0.98 0.90 0.06 0.92 
RF 0.92 0.49 0.22 0.91 
Triple negative 
vs rest of 
tumors 
KNN 0.78 0.31 0.37 0.82 8 
 SVM 0.98 0.95 0.05 0.97 
RF 0.80 0.42 0.36 0.84 
Her2 vs        
rest of tumors 
KNN 0.69 0.15 0.44 0.60 7 
 SVM 0.98 0.94 0.05 0.96 
RF 0.78 0.00 0.41 0.50 
Luminal B vs 
rest of tumors 
KNN 0.76 0.38 0.41 0.72 16 
 SVM 0.97 0.93 0.07 0.96 
RF 0.80 0.45 0.41 0.67 
Luminal A vs 
rest of tumors 
KNN 0.70 0.02 0.44 0.61 3 
 SVM 0.98 0.97 0.04 0.98 
RF 0.71 -0.05 0.44 0.57 
KNN: K Nearest Neighbor, SVM: Support Vector Machine, RF: Random Forest, MCC: Mathews 
Correlation Coefficient, RMSE: Root Median Square Error, AUC: Area Under the Curve. 
 
 
 
 
Supplementary Figure S1. Differences in size of triple negative tumors expressing high or low levels 
of miR-30c-5p.  
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